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ABSTRACT 
Colitis associated cancer (CAC) is a chronic inflammation driven colon cancer among 
individuals with Inflammatory Bowel Disease. Its development is associated with the 
inflammation-dysplasia-carcinoma pathway which differs from the adenoma-carcinoma pathway 
of sporadic colon cancer (CRC). Matrix Metalloproteinases are zinc-dependent endopeptidases 
against extracellular matrix proteins expressed in the gastrointestinal tract during inflammation. 
We have shown that Matrix Metalloproteinase 9 (MMP9) plays a protective role in CAC 
contrary to its inflammatory role in acute-colitis. I hypothesize that epithelial-derived MMP9 
mediates tumor suppression in CAC by regulating genomic stability via Notch1 activation. This 
study identifies the role of epithelial derived-MMP9 in CAC via “MMP9-Notch1-ARF-p53 axis” 
pathway which regulates apoptosis, cell-cycle arrest and DNA damage. This study also identifies 
the role of epithelial-derived MMP9 in maintaining genomic stability by reducing reactive 
oxygen species and activating mismatch repair mechanisms. Thus, MMP9 expression could 
potentially be a natural way to suppress inflammation induced colon cancer.   
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1 INTRODUCTION  
1.1 Inflammatory Bowel Disease 
IBD, such as Crohn’s Disease (CD) and ulcerative colitis (UC), are chronic inflammatory 
conditions that affects the gastrointestinal (GI) tract as well as the colonic mucosal (Molodecky, 
Soon et al. 2012). CD can affect any site of the GI tract from the mouth to the anus, mostly the 
terminal ileum, and UC occurs predominately at the distal end of the colon (Hanauer and 
Sandborn 2001). These diseases affect approximately 1 to 4 million individuals in the U.S 
(Baumgart and Sandborn 2007). IBD causes epithelial barrier disruption by affecting major 
components of the intestinal GI tract such as epithelial cells, goblet cells, immune cells, and 
intestinal commensal bacterial types (Baumgart and Sandborn 2007, Xavier and Podolsky 2007). 
It is characterized by relapses (acute flare) and remissions which involve immune-mediated 
tissue injury followed by repair (Fiocchi 1998). Acute or short-term inflammation is a beneficial 
response to tissue damage and pathogenic challenges. However, unregulated inflammation may 
lead to chronic and malignant cell transformation resulting in cancer(Lynch, Drescher et al. 
2014).  
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1.2  Colitis Associated Colon Cancer 
 
Figure 1. Schematic of Colitis Associated Cancer Progression (above) and Sporadic Colon 
Cancer progression (below) 
 
Individuals with chronically active UC and CD have up to a 50% (depending on 
population cohort) risk of developing colitis-associated cancer (CAC) (Rogler 2014). The risk of 
developing CAC increases with the length of the disease in correlation with the severity of 
inflammation (Choi and Zelig 1994, Itzkowitz 2006). Although both sporadic colon cancer 
(CRC) and CAC are colon malignancies, several features make CAC distinct from (CRC) 
(Walter, Harper et al. 2013). CAC has gathered much attention due to its different molecular 
events associated with various stages of colon tumorigenesis including initiation, promotion and 
progression as compared to CRC (Terzic, Grivennikov et al. 2010). The development of CAC is 
associated with the inflammation-dysplasia-carcinoma pathway that is significantly different to 
the adenoma-carcinoma pathway of CRC(Waldner and Neurath 2015). In CAC, mutations in the 
tumor suppressor gene p53 are the first to occur followed by k-ras mutations and adenomatous 
polyposis coli (APC) mutations occur in the later stage (Walter, Harper et al. 2013). Unlike CRC 
that arise from adenomatous polyps, CAC develops commonly in flat dysplastic tissues in 
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individuals pre-exposed to IBD and have more polyp formation in the distal colon region 
(Terzic, Grivennikov et al. 2010).  Also, CAC has a higher percentage of chromosome instability 
(CIN) and microsatellite instability (MSI) than CRC (Fukata and Abreu 2008). In CAC due to 
chronic inflammation, proinflammatory cytokines IL-1β and TNF-α secrete reactive oxidative 
species (ROS) and reactive nitrogen intermediates (RNI) (Kraus and Arber 2009). This leads to 
persistent inflammation in epithelium stimulating ROS overproduction within the epithelial cells 
(Terzic, Grivennikov et al. 2010). Consequently, the imbalance between generation and 
elimination of ROS and RNI stimulates oxidative stress inducing DNA damage (Kraus and 
Arber 2009).  
1.3 Matrix Metalloproteinases  
MMPs are zinc-dependent neutral endopeptidases that have proteolytic activity against 
extracellular matrix (ECM) proteins (Sternlicht and Werb 2001, Egeblad and Werb 2002, 
Okamoto and Watanabe 2005, Garg, Sarma et al. 2010). Their targets include proteinases, 
clotting factors, chemotactic molecules, latent growth factors, cell surface receptors, and cell-cell 
adhesion molecules that make them able to regulate many biological processes (Cao, Drews et al. 
1998, Curci, Liao et al. 1998, Sun, Wenger et al. 1999, Sternlicht and Werb 2001). MMPs are 
expressed in the GI tract by immune cells (neutrophils, macrophages, and lymphocytes) as well 
as epithelial cells during inflammation (Baugh, Perry et al. 1999, Sternlicht and Werb 2001, 
Castaneda, Walia et al. 2005). They regulate innate and acquired host defenses by facilitating 
inflammatory cell recruitment across the epithelium and endothelial basement membrane (Ravi, 
Garg et al. 2007). In CRC, MMPs have been extensively studied to play a significant role in 
development and progression (Walter, Harper et al. 2013). However, there are no studies 
showing the mechanistic link between MMPs with CAC (Walter, Harper et al. 2013).  
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1.4 Matrix Metalloproteinase 9 Structure and Activation 
 
Figure 2. 2D structure of Matrix Metalloproteinase 9  
 
MMP9, also called 92-kDa type IV collagenase or gelatinase B, plays a key role in ECM 
degradation and is involved in tissue remodeling (Yabluchanskiy, Ma et al. 2013). It is 
undetectable from all healthy adult tissues but is the highest expressed protease during 
inflammation in IBD (Baugh, Perry et al. 1999). This protease consists of an NH2-terminal 
prodomain, a catalytic domain, a linker domain, and a COOH-terminal hemopexin domain-like 
domain (Chen and Greene 2004). The prodomain of contains a “bait region” in the N-terminal, 
that mediates activation by being cleaved by targeted serine proteinases, leading to partial 
activation followed by full activation via autocatalytic cleavage (Visse and Nagase 2003). 
Latency is maintained by an unpaired cysteine sulfhydryl group near the C-terminal end of the 
propeptide domain within a conserved cysteine motif, called the “cysteine switch”(Visse and 
Nagase 2003). This sulfhydryl acts as a fourth ligand for the active site zinc ion, that is bound to 
three histidine residues in the zinc binding domain of the catalytic region(Vandooren, Van den 
Steen et al. 2013). The catalytic domain contains consists a zinc ion, and three homologous type 
II fibronectin repeats (Yabluchanskiy, Ma et al. 2013). The zinc ion is coordinated with the 
cysteine switch motif to keep MMP-9 inactivated (Rowsell, Hawtin et al. 2002). Once activated, 
the zinc ion is used for proteolytic activity (Rowsell, Hawtin et al. 2002). Also, MMP-9 has a 
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heavily O-glycosylated fibronectin-like type II domain that is essential in binding denatured 
collagen and gelatin (O'Farrell and Pourmotabbed 1998, Opdenakker, Van den Steen et al. 2001). 
MMP9 is unique from other MMPs due to a central highly O-glycosylated  domain between the 
catalytic and terminal hemopexin domains, which allows for their independent movements 
(Ravi, Garg et al. 2007). The hemopexin domain is required for substrate specificity.  
Interference of the cysteine-zinc interaction in the cysteine switch leads to the activation 
of MMP9 (Cornelius, Nehring et al. 1998, Visse and Nagase 2003). Activation of MMP-9 by 
serine proteases are mediated by cleavage specificity of the bait region via an initial proteolytic 
attack that partially activates it (Visse and Nagase 2003). Once the part of the propeptide is 
removed, it will destabilize the rest of the propeptide that includes the cysteine switch zinc 
interaction allowing for full activation via intermolecular processing (Bini, Itoh et al. 1996). 
Once activated, a substrate will bind onto the catalytic site cleft, its carbonyl group of the peptide 
coordinates with the active-site zinc (Visse and Nagase 2003). The peptide undergoes hydrolysis, 
displacing water from the zinc atom, which facilitates a nucleophilic attack of the water molecule 
on the scissile peptide bond of the carbonyl group (Llano, Pendas et al. 1999). The specificity 
pocket, on the right of the catalytic zinc, accommodates the side chain of the substrate residue 
which becomes the new N-terminus after cleavage (Llano, Pendas et al. 1999).  
1.5 Matrix Metalloproteinase 9 Expression 
MMP9 is expressed in the GI tract by immune cells and epithelial cells during 
inflammation (Baugh, Perry et al. 1999, Sternlicht and Werb 2001, Castaneda, Walia et al. 
2005). It is the most expressed protease in IBD as well as being expressed in several other 
inflammatory diseases such as asthma, rheumatoid arthritis, nonsteroidal anti-inflammatory 
drugs (NSAID)-induced gastric ulcers (Bailey, Hembry et al. 1994). NFκB is required for 
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production MMP9 (Bond, Chase et al. 2001, Okamoto, Akaike et al. 2001). AP-1, which has two 
binding sites on the MMP9 promoter, also stimulates the production of MMP9 from its 
activation (Wasylyk, Gutman et al. 1991, Woessner 1991). Cooperation between AP-1 and 
NFκB is required for MMP9 transcription induction because the AP-1 occupation is not 
sufficient. TNF-α and IL-1β are two cytokines that are shown to increase NFκB and AP-1 (He, 
Joiner et al. 2011). Suppression of MMP9 transcription is a result of interference with binding of 
NFκB and AP-1 to the promoter region such as Kiss-1, a suppressor of cancer cell proliferation 
and metastasis (Vandooren, Van den Steen et al. 2013).  
MMP9 trafficking after translation is different in neutrophils as opposed to other cells 
(Vandooren, Van den Steen et al. 2013). In neutrophils, it is produced rapidly and pre-stored in 
zymogen granules to be secreted within minutes upon an inflammatory stimulus (Van den Steen, 
Proost et al. 2002). It is then used for degradation of the ECM with activation of major 
proangiogenic factors such as vascular endothelial growth factor (VEGF) and fibroblast growth 
factor-2 (Jonsson, Lundberg et al. 2011, A 2013). Other cells such as macrophages and epithelial 
cells rely on de novo synthesis prior to the secretion of MMP9, which takes at least several hours 
(Opdenakker, Van den Steen et al. 2001). Upon activation, MMP9 can be found in small Golgi-
derived cytoplasmic vesicles that are associated with stable microtubules and kinesin transport 
proteins (Vandooren, Van den Steen et al. 2013). My lab has demonstrated epithelial not 
neutrophil-derived MMP9 mediates tissue damage during intestinal inflammation (Castaneda, 
Walia et al. 2005). The mechanism by which it mediates tissue damage is not well known (Ravi, 
Garg et al. 2007). Potential mechanisms by which it mediates this response could be from 
defective re-epithelialization, adhesion complex integrity in impaired wound healing, increased 
endothelial permeability, and activation of fibrin(ogen), IL-1β, and TGF-β (Alexander and Elrod 
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2002, Mohan, Chintala et al. 2002). We have shown exogenous MMP9 inhibits epithelial cell 
adhesion which is required for epithelial cells to migrate and attach to appropriate matrix after 
damage (Castaneda, Walia et al. 2005). During inflammation, MMP9 plays an important role in 
post-translation regulation of cadherin, occluding adhesive activities and proteolytic cleavage of 
occluding or E-cadherin ectodomain (Papon, Lechapt-Zalcman et al. 2006, Xue, Le et al. 2006). 
This results in the disassembly of tight and adherens junctions leading to impaired cell 
migrations and wound healing in cornea, skin, and endothelial cells (Stetler-Stevenson, Krutzsch 
et al. 1989, Matsubara, Zieske et al. 1991). 
1.6 DUAL ROLE OF MATRIX METALLOPROTEINASE 9 IN CANCER 
Studies have shown that inhibition of gelatinases (MMP9 and MMP2) results in regression 
of tumor growth (Lubbe, Zhou et al. 2006) (Bjorklund and Koivunen 2005). Sinnamon et al have 
shown that in Adenomatous polyposis coli (APC)-Min mice genetically deficient in MMP9 
expression had fewer tumors than littermate controls due to altered proliferation by MMP9 among 
APC-Min adenoma cells (Sinnamon, Carter et al. 2008). On the other hand, Burg-Roderfeld et al 
(Burg-Roderfeld, Roderfeld et al. 2007) has shown that MMP9 hemopexin domain has an 
inhibitory effect on migration and adhesion of colorectal carcinoma cells. Another study by Pozzi 
et al (Pozzi, LeVine et al. 2002) showed that reduction of plasma levels of MMP9, in either normal 
or integrin alpha1-null mice, leads to decreased synthesis of angiostatin and consequent increased 
tumor growth and vascularization and was also supported by the study of Bjorklund and Koivunen 
(Bjorklund and Koivunen 2005). In melanoma, increased expression of MMP9 is found initially, 
but is reversed at the later stage (van den Oord, Paemen et al. 1997). It has been reported that in 
breast and colon cancer, MMP9 expression has been correlated with both increased and decreased 
survival and formation of distant metastasis (Bjorklund and Koivunen 2005) (Pacheco, Mourao et 
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al. 1998). Recently some studies have also shown that MMP9 has a protective role in different 
malignancies such as chronic inflammation in lung and liver (Liu, Turkoz et al. 2011, Gonzalez-
Arriaga, Pascual et al. 2012). 
Our lab has shown that MMP9 knockout animals were more susceptible to CAC (Garg, 
Sarma et al. 2010).  Our group has also shown that MMP9 activates transcription factor Notch1 
(Garg, Jeppsson et al. 2011). Notch1 plays various important roles during embryogenesis and 
tissue homeostasis, and also has a dual role in cancer biology (Garg, Jeppsson et al. 2011). 
Consequently, MMP9 could play a protective role in CAC in contrast to its inflammation 
mediator function in acute colitis (Talora, Sgroi et al. 2002, Talora, Cialfi et al. 2005) (Garg, 
Sarma et al. 2010). Also, GI cancers consist mainly of epithelial cells with p53 mutations 
occurring initially in CAC. Thus, I hypothesize that epithelial derived MMP9 activates p53 
via Notch1 signaling as well as regulating genomic stability to acts as a tumor suppressor in 
CAC.   
 
2 EXPERIMENT EPITHELIAL DERIVED MATRIX METALLOPROTEINASE 9 
ACTS AS A TUMOR SUPPRESSOR IN COLITIS ASSOCIATED COLON CANCER 
BY ACTIVATING P53 VIA NOTCH 1 SIGNALING 
(This work is mainly based on the published paper in Oncotarget. 2017;8(1):364-78. In this 
project, the author is obliged to Dr. Pallavi Garg and Dr. Didier Merlin for their great 
contributions to Colitis Associated Cancer research.) 
2.1 Introduction 
The role of inflammation in cancer development has been indicated as early as in 18th 
century (Landskron, De la Fuente et al. 2014). In the following years, an association between 
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chronic inflammation and cancer has been strongly highlighted which gathered much attention. 
Inflammation is a beneficial response to tissue damage and pathogenic challenges, though 
unregulated inflammation may transform into chronic and thereby inducing malignant cell 
transformation in the tissue environment. Inflammatory bowel disease (IBD), which primarily 
includes ulcerative colitis (UC) and Crohn's disease (CD), involves inflammation of all or part of 
digestive tract. Patients with chronically active UC and CD inevitably have significantly higher 
risk (as high as 50% depending on the population cohort) of colitis associated cancer (CAC) 
(Rogler 2014). CAC risk increases with the duration of the disease and correlates positively with 
the severity of inflammation. CAC is a subtype of colorectal cancer (CRC) yet uniquely different 
from it (Walter, Harper et al. 2013). CAC progresses through ‘dysplasia-carcinoma axis’ while 
CRC progression is through ‘adenoma-carcinoma axis’(Ullman and Itzkowitz 2011). In CAC, p53 
mutations are the first ones to be detected followed, by KRAS and APC mutations respectively. On 
the other hand in CRC APC mutations are the first ones to be identified followed by KRAS 
mutations and p53 mutations respectively (Ullman and Itzkowitz 2011, Walter, Harper et al. 2013). 
It is known that inflammatory responses dissect oncogenic signaling pathways such as apoptosis, 
proliferation, angiogenesis etc. 
In this context the relation between tumor cells and its surrounding normal tissue, in which 
a large family of proteolytic enzymes- proteases are involved cannot be ignored. Proteases play 
important roles in a wide variety of biological processes as well as multiple diseases including 
cancer (Lopez-Otin and Bond 2008). Among the wide variety of proteases, the matrix 
metalloproteinases (MMPs) have significantly played the role of effectors in cancer progression 
due to their ability to degrade the protein components of the extracellular matrix (ECM) and the 
basement membranes. Thus provide an access for tumor cells to the vascular and lymphatic 
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systems and facilitating the generation of metastasis (Walter, Harper et al. 2013). MMPs are a 
family of Zn2+ dependent extracellular matrix degrading endopeptidases that share common 
functional domains and activation mechanisms (Vu and Werb 2000). MMPs are the only 
mammalian enzymes capable of catalyzing cleavage of the interstitial collagen, types I, II, III or 
IV, in their native triple helical form, at the neutral pH of the extracellular space (Vu and Werb 
2000). MMPs being essential regulators of ECM and basement membrane are involved at all 
junctures of inflammation as well as tumor progression- including proliferation, adhesion, 
migration, angiogenesis, senescence, apoptosis, cytokine and chemokine bioactivity and evasion 
of the immune system (Matsubara, Zieske et al. 1991) (Lopez-Otin and Bond 2008, Al-Dasooqi, 
Gibson et al. 2009, Walter, Harper et al. 2013). In recent years, studies to identify the molecular 
basis and pathophysiology of CAC have been attempted. However, the precise role of MMPs in 
mediating CAC is still unexplored except few sporadic studies (Newell, Matrisian et al. 2002, 
Garg, Jeppsson et al. 2011, Walter, Harper et al. 2013) (Garg, Sarma et al. 2010). 
Among the 25 known mammalian MMPs (Giannandrea and Parks 2014), MMP9 is unique 
as its protein expression and activity is undetectable in most healthy adult tissues including the 
intestine and colon but is highly expressed in a variety of inflammatory states. We have shown 
that epithelial cell-derived MMP9 mediates tissue damage during colitis (Castaneda, Walia et al. 
2005) (Garg, Vijay-Kumar et al. 2009) (Liu, Patel et al. 2013). We have also shown that despite 
being a mediator of acute colitis, MMP9 plays an opposite but protective role in the development 
of CAC (Garg, Sarma et al. 2010) (Garg, Jeppsson et al. 2011). Aim of the present study is to 
determine if epithelial derived- MMP9 is responsible for this contrasting but defensive role of 
tumor suppressor in CAC. We also sought to determine the underlying the molecular mechanism 
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by using MMP9 transgenic mice, Tg-villin-MMP9 (TgM9) that specifically overexpresses MMP9 
in the colonic epithelium. 
2.2 Methods 
2.2.1 Animal Models 
All animal procedures were in compliance with the Guide for the Care of Use of Laboratory 
Animals from the US Public Health Service and with approval from the Animal Care Committee 
of Georgia State University. As described previously (Liu, Patel et al. 2013), 10 weeks old gender 
matched TgM9 and their wild-type (WT) littermates obtained while crossing the hetz of TgM9 of 
C57/B6 background were used for the study at the start of the experimental protocol. Extensive 
characterization of TgM9 has been published previously by us (Liu, Patel et al. 2013)  and some 
new data has been added in supplementary Figure S1. As described previously (Castaneda, Walia 
et al. 2005) (Garg, Sarma et al. 2010), 10 weeks old gender matched MMP9-/- and WT mice of 
C57/B6 background were also used for the study They were maintained on a 12-hour dark-light 
cycle and allowed free access to nonpurified diet pellets and tap water.  
2.2.2 Colitis Associated Cancer Induction  
Both TgM9 (n=20) and WT (n=18) were divided into two groups- one group was induced with 
CAC and another group was given water only. The CAC group of TgM9 (n=20) and WT (n=18) 
were exposed to 3% DSS (w/v) (MP Biomedicals, Salon, OH) by oral administration through their 
drinking water ad libitum for 7 days. On day 8, their water was changed to regular drinking water. 
On day 21, their drinking water was changed back to 3% DSS for the second cycle of a week. This 
was followed by two weeks of recovery period with regular drinking water. On day 85, the mice 
were sacrificed after 3rd cycle of DSS and recovery. Colonscopy images (Xenon Nova 475, 
STORZ, Tuttlingen, Germany) were taken as well as colons being opened longitudinally to count 
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the number of polyps and dysplastic lesions. We monitored body weight, stool consistency, and 
stool occult blood of all the mice during DSS and recovery cycles. 
2.2.3 Hematoxylin and Eosin staining 
Swiss rolls of the colon of mice induced with CAC were collected and H&E staining was 
performed. H&E stained sections were used to calculate the histological score based on crypt 
damage, infiltration of neutrophils, and foci of ulceration in the analyzed colons (Cooper, Murthy 
et al. 1993, Cooper, Murthy et al. 2000). 
2.2.4 TUNEL staining 
As described previously (Liu, Patel et al. 2013), paraffin sections of colons were 
deparaffinized and stained for TUNEL. Quantification of apoptosis was performed by counting 
number of apoptotic cells per crypt divided by total number of epithelial cells in the same crypt 
and was expressed as percentage. For each mouse in each group 12 crypt were counted. 
2.2.5 Protein extraction and western blot analysis 
As described previously (Garg, Jeppsson et al. 2011), for WB analysis, mucosal stripping 
was obtained from the TgM9 and WT mice (n=20 per group) with and without CAC after the 
sacrifice. The antibodies used were anti-MMP9 (Abcam, Cambridge, MA), anti-NICD (Abcam), 
anti-caspase-3 (Cell Signaling, Beverly, MA) anti-p53 (Cell Signaling), anti-p21WAF1/Cip1 (BD 
Bioscience, San Jose, CA), anti-cyclin D1 (Santa Cruz, Dallas, TX), anti-Cyclin A (Cell 
Signaling), anti-Cyclin E1 (Santa Cruz), anti-γH2AX (Abcam), anti-p19ARF (Abcam), and anti-
p14ARF (Abcam). Goat anti-mouse secondary antibody (1:2000; Bio-Rad, Hercules, CA) or goat 
anti-rabbit secondary antibody (1:2000, Bio-Rad) were used. Densitometry graphs were generated 
by using image acquisition and analysis software by VisionWorksLS Analysis Software (UVP, 
Upland, CA). 
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2.2.6 Cell Culture and transfection 
As described previously (Garg, Jeppsson et al. 2011), MEF cells, obtained from MMP9-/- 
and WT mice. As describe previously stably transfected HCT116 cell lines (expressing wild type 
p53, a generous gift from Dr. VW Yang, Stony Brook University, NY) with and without MMP9 
(Garg, Jeppsson et al. 2011) were used to analyze the cell proliferation assay and cell cycle arrest. 
They were transfected for 72 h with a pEGFP plasmid with and without the MMP9 gene in 6 well 
plate. The transfected clones were selected under an antibiotic (Geneticin; GIBCO, Grand Island, 
NY). These transfected clones were screened for MMP9 expression and the three highest MMP9 
expressing clones were selected for HCT116 cell line and two highest MMP9 expressing clones 
were selected for MEFs, and were sorted via flow cytometry (BD Biosciences).  
2.2.7 Cell proliferation assay 
HCT116 cells were seeded in T25 cm2 flasks at the density 105 per mL medium. After 24 h, 48 h 
and 72 h incubations, cells were counted by automated cell counter (Countess, Invitrogen, Grand 
Island, NY). Each experiment was done in triplicates 
2.2.8 Statistical analysis 
As described previously (Liu, Patel et al. 2013), data are presented as means ± SE. Groups 
were compared by Student’s t-test. P values <0.05 was considered statistically significant.  
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2.3 Results 
2.3.1 Constitutive expression of MMP9 in colonic epithelium exhibited resistance to CAC 
 
Figure 3. Overexpression of MMP9 in colonic epithelium exhibited resistance to CAC 
(A) The line graph representation of change in body weight of TgM9 mice (blue line) and WT 
mice (orange line) during three cycles of DSS (D1, D2 and D3) followed by three recovery 
cycles (R1, R2 and R3). TgM9 mice (green line) and WT mice (red line) without CAC induction 
shows the body weight change. (B) The top panel shows representative colonoscopy images 
from two different WT mice and bottom panel shows representative colonoscopy images from 
two different TgM9 mice in CAC. Red arrows indicate flat polyps a characteristic feature of 
CAC polyps. (C)  The bar graph presentation of number of polyps among TgM9 mice (blue bar) 
and WTs (grey bar) in CAC. (D) The bar graph presentation of dysplastic lesions counts among 
TgM9 mice (blue bar) and WTs (grey bar) in CAC, NS means non-significant. Each bar 
represents mean ± S.E., *p< 0.05 
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Both TgM9 and their wild type (WT) littermates were induced with CAC as described in 
‘Materials and Methods’ section and were sacrificed after 85 days. Both groups of mice were 
monitored for weight loss during the entire length of the experiment. TgM9 mice showed 
significantly more weight loss compared to WT littermates at the end of 1st cycle of dextran sodium 
sulfate (DSS) (Figure 1A). However, at the end of 2nd cycle of DSS there were no significant 
changes in the body weight of TgM9 mice compared to WTs. On the other hand, TgM9 mice 
started displaying a significant weight gain at the end of 2nd recovery cycle (Figure 1A). They also 
exhibited significantly lower body weight loss compared to WTs at the end of 3rd cycle of DSS. 
This trend continued until the end point of the protocol i.e. till the day of sacrifice. TgM9 and WT 
mice exhibited a parallel and comparable increase in body weight without CAC as a control group 
(Figure 1A). Figure 1B shows the colonoscopy view indicating that thickening of mucosal layer 
due to inflammation and number of polyps (as shown by red arrows), were significantly lesser 
among TgM9 mice compared to WTs in CAC. Figure 1C is the bar graph presentation of tumor 
incidence among TgM9 supporting the colonoscopy data. There was significantly less number of 
polyps among TgM9 mice (1.7±0.64) compared to WT littermates (4.1±1.2) in CAC. In Figure 
1D, TgM9 showed a trend of fewer dysplastic lesions (2.2±0.31) compared to their WT littermates 
(3±1.09) in CAC, however the difference was not significant. These data together indicates that 
TgM9 mice overexpressing MMP9 in colonic epithelium were more protected compared to WTs 
in CAC. 
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2.3.2 Constitutive expression of MMP9 in colonic epithelium was associated with lower 
histological score and apoptosis 
 
Figure 4. Overexpression of MMP9 in colonic epithelium was associated with lower 
histological score and apoptosis in CAC. 
(A) H&E staining of Swiss rolls of the colons from TgM9 and WT mice in CAC indicating less 
damage to crypt architecture.  Left panel shows X20 magnification and right panel shows X10 
magnification. (B) The bar graph presentation of histological score calculated on three 
parameters: infiltration of neutrophils, loss of crypt architecture and foci of ulceration of TgM9 
mice (blue bar) and WTs (grey bar) in CAC. (C) The top panel shows DAPI blue colored 
staining for nucleus, middle panel shows TUNEL staining as green fluorescent nuclei and lower 
panel shows the overlay images of greenish yellow nuclei of apoptotic cells as indicated by red 
arrow, magnification used was X10. (D)  The bar graph representation of the quantification of 
apoptosis as the percentage of apoptotic nuclei/total number of cells per crypt among TgM9 mice 
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(blue bar) and WTs (grey bar) in CAC, number of crypts counted were 12 for each mice. Each 
bar represents mean ± S.E., *p< 0.05 and **p< 0.005. 
 
Figure 2A represents the Haematoxylin and Eosin (H&E) staining indicating decreased 
crypt architecture damage, lesser infiltration of neutrophils, fewer foci of ulceration and 
dysplastic lesions among TgM9 mice compared to WTs.  Figure 2B is the bar graph presentation 
of the histological score based on the parameters described in ‘Materials and Methods’ section, 
indicating that TgM9 mice had significantly lower histological score (4.5±1.9) compared to WTs 
(8.2±0.6) in CAC.  Abnormal apoptosis and/ or irregular proliferation are the characteristic 
features of tumor cells. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) staining was performed to assess apoptosis in the colonic epithelium of TgM9 mice. In 
Figure 2C top panel shows blue colored Diamidino-2-Phenylindole, Dihydrochloride (DAPI) 
staining for nuclei, middle panel shows the green fluorescent cells as apoptotic cells and lower 
panel is the merged/ overlay image of greenish yellow fluorescence indicating that there was a 
significant increase in apoptosis (as represented by red arrows at the apical surface of crypts) 
among the TgM9 mice compared to WTs in CAC. Figure 2D is the bar graph presentation of the 
quantification of apoptotic cells among TgM9 mice and WTs in CAC, indicating that TgM9 
mice had significantly higher (23.29±3.2) compared to WTs (4.24±0.07) in CAC. Together, 
these results indicate that in CAC epithelial derived- MMP9 maintained crypt architecture, 
mucosal layer integrity and associated with fewer dysplasia and increased apoptosis compared to 
WTs. 
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2.3.3 TgM9 mice exhibited altered protein expression of active Notch1, p53, p21 WAF1/Cip1 and 
Cyclin E 
 
Figure 5. Overexpression of MMP9 in colonic epithelium exhibited altered protein 
expression of NICD, p53, caspase-3, p21 WAF1/Cip1 and Cyclin E. 
WBs of protein (25μg/lane) from mucosal stripping of the TgM9 and WTs with CAC were 
performed and probed with (A) anti-MMP9; (B) anti-NICD; (C) anti-p53; (D) anti- Caspase-3; 
(E) anti-p21WAF1/Cip1 and (F) anti-Cyclin E. The loading control for each blot was β-tubulin 
or GAPDH. Each blot was a representation of three individual experiments. Bar graphs are the 
representation of densitometry evaluations of the western blots. Each bar represents mean ± S.E., 
*p< 0.05. 
 
Our next step was to dissect the mechanistic pathway by which epithelial derived-MMP9 
mediates protection by exhibiting increased apoptosis in CAC. It is a well-recognized fact that 
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p53 is the most common tumor suppressor gene which is mutated in almost all kinds of cancers 
(Leroy, Anderson et al. 2014). Further, p53 mutations are the first ones to occur in CAC (Cooks, 
Harris et al. 2014). We performed western blot (WB) analysis to investigate the levels of protein 
expression of wild-type p53 (non-mutated) in association with MMP9 overexpression in colonic 
epithelium. We observed increased apoptosis through TUNEL staining hence we wanted to 
explore apoptosis associated proteins. There was a significant increase in the protein expression 
of MMP9 among TgM9 mice (Figures 3A, lanes 4-6) compared to their WT littermates (Figure 
3A, 1-3) in CAC. This blot also confirms the authenticity of MMP9 overexpression in our TgM9 
mice model. There was also a significant increase in the protein expression of NICD (Notch 
intracellular domain/ active Notch1) among TgM9 mice (Figures 3B, lanes 4-6) compared to 
their WT littermates (Figure 3B, 1-3) in CAC. WB analysis of apoptosis associated proteins 
(Figures 3C and 3D) showed significantly increased protein levels of p53 and caspase-3 (Figures 
3C and 3D) among TgM9 mice (lanes 4-6) compared to WTs (Figures 3B and 3C, lanes 1-3 
respectively). p21WAF1/Cip1 is a well-documented protein involved in cell cycle regulation and is 
also a downstream target of p53 (Harper, Adami et al. 1993). Therefore, WB analysis was 
performed to assess the protein expression of p21WAF1/Cip1 among TgM9 mice in CAC. Figure 3E 
shows that there was a significant increase in the protein expression of p21WAF1/Cip1 among TgM9 
mice (lanes 4-6) compared to their WT littermates (lanes 1-3) in CAC. Cyclin E, which is a cell 
cycle regulatory protein and forms a complex with p21WAF1/Cip1 (Harper, Adami et al. 1993) was 
also observed to be significantly higher among TgM9 mice (Figure 3F, lanes 4-6) compared to 
WTs (Figure 3F, lanes 1-3). Each blot was normalized for loading by immunoblotting with 
housekeeping genes- β tubulin or GAPDH. Supplementary Figure3 represents the protein 
expressions of MMP9, NICD, p53, Bax1, p21 WAF1/Cip1 and Cyclin E among TgM9 compared to 
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WT both exposed to water only (without CAC). These results together indicate that in CAC, 
epithelial derived- MMP9 is associated with activation of p53. p53 activation may lead to 
caspase-3 dependent apoptotic pathway and cell cycle cell cycle arrest via activation of its 
downstream target p21WAF1/Cip1. 
2.3.4 Re-expression of MMP9 in MMP9-/- mouse embryonic fibroblast (MEFs) resulted in 
increased expression of NICD, p53, p21WAF1/Cip1, Bax1, and Cyclin A 
 
Figure 6. Overexpression of MMP9 in MMP9-/- MEFs resulted in increased expression of 
NICD, p53 and p21WAF1/Cip1. 
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WBs of protein (25μg/lane) from whole cell lysate of stably transfected MMP9-/- MEFs with and 
without pEGFP-MMP9 plasmid were performed and probed with (A) anti-MMP9; (B) anti-
NICD; (C) anti-p53; (D); anti-p21WAF1/Cip1 (E) anti-Bax-1; and (F) anti-Cyclin A. The 
loading control for each blot was β-tubulin or GAPDH. Each blot was a representation of three 
individual experiments. Each blot was a representation of three individual experiments. Bar 
graphs are the representation of densitometry evaluations of the western blots. Each bar 
represents mean ± S.E., *p< 0.05. 
 
As a proof of principle model, to support our hypothesis that MMP9 plays a protective role 
in CAC and activates p53 resulting in increased apoptosis and cell cycle arrest, MMP9-/- MEFs 
stably transfected with and without MMP9-GFP plasmids were used and results were compared 
with WT MEFs.  Figure 4A shows the transfection efficiency of the MMP9-GFP plasmid into 
the MMP9-/- MEFs cells by WB, indicating a significant increase in MMP9 expression (lanes 5-
6, slightly higher band due to pEGFP plasmid) compared to vector control (lanes 3-4) and similar 
to WT MEFs (lanes 1-2). Figures 4B, 4C and 4D displays that re-rexpression of MMP9 in 
MMP9-/-/MMP9-GFP MEFs (MMP9+/+) was associated with significantly increased expression 
of NICD , p53 and p21WAF1/Cip1 (lanes 4-6) compared to vector control (lanes 3-4) and similar to 
WT MEFs (lanes 1-2) respectively. Figures 4E and 4F shows that MMP9 overexpression in 
MMP9-/-/MMP9-GFP MEFs (MMP9+/+) was also associated with significantly increased 
expressions of, pro-apoptotic factor Bax-1 and cell cycle protein Cyclin A (lanes 4-6) compared 
to vector control (lanes 3-4) and similar to WT MEFs (lanes 1-2) respectively. Each blot was 
normalized for loading by immunoblotting with housekeeping genes- β tubulin or GAPDH. 
Taken together, our in vitro data using stably transfected MMP9-/- MEF cell line with and 
without MMP9 indicate that MMP9 activates p53 and p21WAF1/Cip1 via Notch1 resulting in 
increased apoptosis and cell cycle arrest respectively. 
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2.3.5 Overexpression of MMP9 in human colon carcinoma cell line HCT116 displayed 
decreased cell proliferation and cell cycle arrest in S phase of cell cycle 
 
Figure 7. Overexpression MMP9 in human colon carcinoma cell line HCT116 displayed 
decreased cell proliferation, initiates cell cycle arrest in S phase and decreased DNA 
damage. 
(A) The bar graph presentation of the number of stably transfected HCT116 cells with MMP9 
(blue) and without MMP9/vector (grey) at 24, 48 and 72 hours respectively. Each bar represents 
mean ± S.E., *p< 0.005. (B) WB of protein (25μg/lane) from whole cell lysates of stably 
transfected HCT116 cells with and without MMP9 were performed and probed with anti-Cyclin 
D1. (C) The bar graph presentation of FACS data showing number of cells in different phases of 
cell cycle- G0/G1, G1, S and G2/M of stably transfected HCT116 cells overexpressing MMP9 
compared to vector control. Each bar represents mean ± S.E., **p< 0.0003 and ***p< 0.0005.  
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WBs of protein (25μg/lane) from whole cell lysate of stably transfected HCT116 cells with and 
without MMP9 were performed and probed with; (D) anti-Cyclin A; (E) anti-Cyclin E; and (F) 
anti-γH2AX. The loading control for each blot was β-tubulin or GAPDH. Each blot was a 
representation of three individual experiments. Each blot was a representation of three individual 
experiments. Bar graphs are the representation of densitometry evaluations of the western blots. 
Each bar represents mean ± S.E., *p< 0.05. 
   
As another mechanistic approach to assess cell proliferation, we determined the role of 
MMP9 in cell cycle regulation. We used stably transfected colon carcinoma human cell line 
HCT116 with and without MMP9 (Garg, Jeppsson et al. 2011) without γ-radiation. As described 
in ‘Material and Methods section’ equal number of HCT116 cells stably transfected with a pEGFP 
plasmid with or without the MMP9 gene were seeded in T252 flask and were counted after 24h, 
48h and 72 h. Figure 5A is the bar graph presentation of the number of stably transfected HCT116 
cells with and without MMP9, indicating that HCT116 cells overexpressing MMP9 (as indicated 
by blue bars) had significantly lower number of proliferating cells compared to the vector control 
at 48 and 72 hours (as indicated by grey bars). Figure 5B indicates that overexpression of MMP9 
is associated with significantly lower levels of Cyclin D1 (another marker of cell proliferation 
(Mamay, Schauer et al. 2001) (Ohta and Ichimura 2000)) (lanes 4-6) compared to vector control 
(lanes 1-3) respectively. Cyclins are the proteins that are involved in regulating cell cycle 
progression (John, Mews et al. 2001) (Grana and Reddy 1995). To recognize the link between 
MMP9 overexpression and cell cycle progression, HCT116 cells with and without MMP9 were 
stained with propidium iodide and were analyzed for different phases (G0/G1, G1, S and G2/M) 
by fluorescence activated cell sorting (FACS) (as described in Material and Methods section) 
technique. Figure 5C displays the bar graph presentation of the percentile of cells in each phase of 
the cell cycle indicating that HCT116 cells overexpressing MMP9 had a significant cell cycle 
arrest (28%±0.71) in S phase compared to vector (28%±0.83) resulting fewer (16%±0.71) MMP9 
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overexpressing cells reaching to G2/M phase compared to vector (29%±0.88). FACS analysis of 
G0/G1 phase indicated a significant increase in apoptotic cells among MMP9 overexpressing cells 
(8%±0.62) compared to vector control (5%±0.92). The lower number of apoptotic cells was due 
to the fact that HCT116 cell line being a carcinoma cell line is apoptosis resistant and requires γ-
radiation (12 Gy) to induce apoptosis (Garg, Jeppsson et al. 2011). Figure 5D and 5E shows that 
MMP9 overexpression is associated with significant increase in protein levels of Cyclin A (lanes 
4-6) and Cyclin E (lanes 4-6) compared to vector control (lanes 1-3) respectively. Each blot was 
normalized for loading by immunoblotting with housekeeping genes- β tubulin or GAPDH. 
Histone H2AX, a variant form of histone H2A, undergoes phosphorylationon serine 139 of its C 
terminal tail in response to DNA damage (Scully and Xie 2013) as an early cellular response. 
Figure 5F displays significant decrease in DNA damage at endogenous levels as indicated by 
decreased expression of γH2AX among MMP9 overexpressing cells (lanes 4-6) compared to 
vector control (lanes 1-3). These data together, demonstrate that MMP9 regulates cell proliferation 
by initiating cell cycle arrest in S phase of the cell cycle, associated with increased expressions of 
Cyclin A and Cyclin E and also protects from DNA damage at endogenous levels.   
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2.3.6 Attenuation of MMP9 in MMP9-/- mice is associated with decreased expression of 
p19ARF an upstream regulatory molecule of wild type/non-mutated p53 
 
Figure 8 MMP9-/- mice showed decreased expression of p19ARF an upstream regulatory 
molecule of p53.  
WB of (30μg/lane) proteins (A) from the mucosal stripping of the colons of WT and MMP9-/- mice 
(n=10 each group) probed with anti-p19ARF; (B) from HCT116 overexpressing MMP9 probed 
with anti-p14ARF (human homologue of p19ARF). The loading control for each blot was β-
tubulin. Each blot was a representation of three individual experiments. Each blot was a 
representation of three individual experiments. Bar graphs are the representation of densitometry 
evaluations of the western blots. Each bar represents mean ± S.E., *p< 0.05. 
 
It has been well documented that ARFs (alternative reading frame, termed p19ARF in 
mouse cells and p14ARF in human cells) and MDM2 (mouse double minute 2 homolog) are main 
regulatory proteins upstream of p53 and regulates its expression (Sharpless and DePinho 1999) 
(Martelli, Hamilton et al. 2001) (Canepa, Scassa et al. 2007). ARF binds to MDM2 and inhibits its 
binding with p53 by sequestering it to nucleus. Once sequestered in nucleus it cannot bind to p53 
and cannot degrade p53 by ubiquitylation (Khan, Guevara et al. 2004) (Zindy, Williams et al. 
2003). To identify the mechanistic link by which MMP9 activates wild type/non-mutated p53, we 
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used WB analyses of upstream regulatory molecules of p53 and observed that at basal level MMP9-
/- mice (Figure 6A, lanes 4-5) compared to WT mice (Figure 6A, lanes-1-3) had significantly 
decreased protein expression of p19ARF. Figure 6B shows significantly increased expression of 
p14ARF (human homologue of p19ARF) among stably transfected HCT116 overexpressing 
MMP9 (lanes 4-6) compared to vector (lanes 1-3). However, at the basal level we didn’t observe 
any changes in the MDM2 expression among MMP9-/- mice (Supplementary Figure S2). We also 
observed that TgM9 mice (Figure 6C, lanes 3-4) had significantly increased expression of p19ARF 
compared to WT littermates (Figure 6C, lanes 1-2) in CAC. These results suggest that the tumor 
suppressive role of epithelial derived-MMP9 is through a novel mechanistic pathway “MMP9-
Notch1-ARF-p53 axis” in CAC (Figure 7).  
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2.4 Conclusion 
 
Figure 9 Schematic representation of “MMP9-Notch1-ARF-p53” mechanistic pathway of 
epithelial derived MMP9 mediated protection in CAC. 
Abbreviations used are: NICD, Notch1 intracellular domain; ARF, alternative reading frame; 
CAC, colitis associated cancer. 
 
CAC is chronic inflammation driven carcinogenesis process, though the exact molecular 
mechanism by which chronic inflammation triggers CAC is still unexplored. Further, in CAC the 
physiological and pathological progression of inflammation to dysplasia and finally to carcinoma 
makes it tough to determine the rate limiting step for therapeutic strategies. It has been reported 
that more than 20% of IBD patients develop CAC within 30 years of disease onset, and less than 
50% of these die from CAC (Lakatos and Lakatos 2008, Walter, Harper et al. 2013). Therefore, 
identification and prognosis of disease risk genes in CAC has been a big hurdle for the efficacy of 
the therapeutic interventions in CAC.  
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Individual roles of MMPs with the initiation and perpetuation of intestinal inflammation 
as well as with the progression of CRC have long been cited in the literature. However, there are 
few sporadic studies discussing the precise role of MMPs in CAC (Newell, Matrisian et al. 2002), 
(Garg, Sarma et al. 2010), (Garg, Jeppsson et al. 2011), (Walter, Harper et al. 2013). At the onset 
of inflammation, similar to the release of chemokines and cytokines, MMP9 is also active and 
highly up-regulated. Although its role has been well understood and documented in contexts of 
acute inflammation and CRC individually. However, the precise role of MMP9 has never been 
studied in the setting of chronic colonic inflammation/CAC. We were the first ones to report the 
novel protective role of MMP9 in CAC (Garg, Sarma et al. 2010) against its convention role of a 
mediator of acute inflammation. We have reported that in CAC attenuation of MMP9 gene was 
associated with increased susceptibility to tumor incidence and tumor burden compared to WTs. 
We have also shown that MMP9-/- mice had significantly higher proliferation and lower apoptosis. 
It has been known that epithelial cells and neutrophil cells are the most important cells involved 
in secreting MMP9 in any tissue/organ. Therefore, to understand the precise mechanism of tumor 
suppressive role of MMP9 in CAC, it is very important to know which MMP9 ‘epithelial-derived’ 
or ‘neutrophil-derived’ is involved. 
In the present study, we used TgM9 mice which can overexpress MMP9 in colonic 
epithelium (Liu, Patel et al. 2013) to identify the role of epithelial derived MMP9 in CAC. We 
observed that overexpression of MMP9 in colonic epithelium is associated with lower tumor 
incidence, and retained crypt architecture and mucosal layer integrity compared to WT littermates 
indicating that TgM9 mice were more protected from ulceration in CAC. In this study we have 
also shown that protection from CAC in TgM9 mice was associated with increased apoptosis 
compared to WTs. To identify the underlying molecular mechanism by which MMP9 mediates 
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protection in CAC, as in vivo model we used TgM9 and WTs and observed that epithelial derived-
MMP9 mediates activation of p53 dependent caspase-3 apoptotic pathway as well as modulated 
the expressions of cell cycle regulatory proteins p21WAF1/Cip1 and Cyclin E via Notch1 signaling. 
Through our ‘Proof of Principle’ model we verified the direct participation of MMP9 as a tumor 
suppressive molecule, by using stably transfected MMP9-/- MEFs with MMP9-pEGFP. We 
observed that by ‘knocking in MMP9 gene’ among MMP9-/- MEFs we could restore the protein 
expressions of NICD, p53, Bax-1, p21WAF1/Cip1 and Cyclin A (which otherwise were either absent 
or low in MMP9-/- MEFs). Our in vitro model of human colonic carcinoma cell line HCT116 stably 
transfected with MMP9 displayed decreased proliferation compared to vector supporting the in 
vivo data of increased apoptosis. FACS analysis indicated cell cycle arrest in S phase among 
MMP9 overexpressing cells compared to vector control. We also observed increased expressions 
of cell cycle regulatory proteins (specifically associated with S phase of the cell cycle) Cyclin A 
and Cyclin E. The most striking and significant data in our eyes were decrease in endogenous 
levels of γH2AX with MMP9 expression as indicated by our HCT116 in vitro model. These results 
together delineate the underlying molecular mechanism of the protective role of epithelial derived-
MMP9 in CAC. Our in vivo and in vitro data showed direct correlation between MMP9 expression 
and ARF expression suggesting the mechanistic pathway by which MMP9 regulates p53 
expression via Notch1 activation (Figure 7). Taken together the data suggest that epithelial 
derived-MMP9 acts as a tumor suppressor by activating MMP9-Notch1-ARF-p53 axis which 
results in increased apoptosis, initiates cell cycle arrest via activating p21WAF1/Cip1 as well as keep 
a check on DNA damage.  
p53 is a well-established tumor suppressor that plays an important role in the development 
of CAC as well as sporadic colon cancers. p53-/- mice are highly susceptible to CAC (Donehower 
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1996) (Chang, Coudry et al. 2007). Cellular stress signals like DNA damage, UV light and 
oncogene activation trigger p53 activation and nuclear translocation. The activation of p53 
modulates tumor suppression by initiating a transcriptional program that results in regulating 
apoptosis through caspase-3 activation or promoting cell cycle arrest or senescence. Among cell 
cycle regulatory proteins that are activated following cellular stress signals, the Cyclin-dependent 
kinase (CDK) inhibitor p21WAF1/Cip1 (also a downstream target of p53) plays essential roles in 
maintaining cellular integrity by inducing cell cycle arrest. Bimolecular complexes of CDKs and 
their Cyclin partners send the signals to responder molecules (e.g., p21WAF1/Cip1) to move the cell 
trough growth and division cycle (Harper, Adami et al. 1993). Any damage to a cell’s genome 
induces the activation of p21WAF1/Cip1, which thereby blocks the activity of Cyclin-CDK complex 
halting the cell cycle progression, until the damage has been repaired. Therefore, the cell cycle 
does not progress and inadvertently stall the copying of damaged DNA sequences. 
It has been well documented that ARF is the positive and MDM2 is the negative upstream 
regulatory proteins of p53. ARF functions as a tumor suppressor by directly binding and interfering 
with the p53-negative regulator MDM2, resulting in stabilization and activation of p53 (Tago, 
Funakoshi-Tago et al. 2014). It is worth to mention here that p19ARF sequences are intertwined 
with p16INK4A (inhibitor of the CDK4 and CDK6 kinases that plays a role in cell cycle arrest). 
The INK4a/ARF is the second most commonly altered gene locus in human cancer after p53 
(Kanellou, Zaravinos et al. 2008). Since in our study we have observed cell cycle arrest in S phase 
and p16INK4A is responsible for G1/S phase cell cycle arrest, in future we would also explore the 
correlation between MMP9 and p16INK4A expressions (Kanellou, Zaravinos et al. 2008). This 
will help in understanding that the inclination of protection equilibrium is more towards apoptosis 
or is more for cell cycle arrest.  
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Genomic instability is critical for tumor progression. Uncontrolled endogenous DNA 
damage due to physiological cellular processes, chronic inflammation or exposure to carcinogens 
encourages faster growth of cancer cells over normal healthy cells by compromising regular 
cellular functions. Genomic instability is therefore directly associated with oncogene activation 
and inactivation of tumor suppressors (Tian, Gao et al. 2015). Studies have suggested that γH2AX 
detection is an efficient biomarker in monitoring cancer progression (Mah, El-Osta et al. 2010). 
Cancer cells typically have increased endogenous γH2AX levels compared to normal cells (Mah, 
El-Osta et al. 2010) (Sedelnikova and Bonner 2006). The downregulation of H2AX can be 
governed by the ARF/p53 pathway. Studies have shown  that mutations in the ARF/p53 module, 
have elevated H2AX levels and exhibit accelerated growth (Yoshioka, Atsumi et al. 2015) 
(Atsumi, Inase et al. 2013). Our study shows that in CAC, MMP9 protects from genotoxicity as 
indicated by decreased endogenous levels of γH2AX and acts a tumor suppressor. 
 MMP9 mRNA, protein level and activity are increased in human and animal models of 
CRC and potentiate colon cancer metastasis (Zucker and Vacirca 2004). In general, 
metalloproteinase inhibitor as well as inhibitors of gelatinases, decrease colon cancer progression 
in animal models (Mook, Frederiks et al. 2004). In mice, it has been reported that genetic ablation 
of MMP9 in APCMin+/- mice resulted in 40% fewer tumors than littermate controls, although tumor 
size distribution remained unaffected (Sinnamon, Carter et al. 2008). On the other hand, some 
studies have shown that in breast and colon cancer, MMP9 expression has been correlated with 
both increased and decreased survival and distant metastasis (Bjorklund and Koivunen 2005). 
However, in recent years, new protective role of MMP9 has also been reported in CRC. It has been 
observed that MMP9 hemopexin domain has an inhibitory effect on migration and adhesion of 
colorectal carcinoma cells (Burg-Roderfeld, Roderfeld et al. 2007). Another study has shown that 
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reduction of plasma levels of MMP9 in either normal or integrin alpha1-null mice leads to 
decreased synthesis of angiostatin and consequent increased tumor growth and vascularization 
(Pozzi, LeVine et al. 2002). MMP9 exhibited protective role against lethal inflammatory mass 
lesions in mouse colon in absence of plasminogen (Hald, Rono et al. 2011) has also been 
documented. 
In very recent years’ protective functions of MMP9 have also been described in other 
cancers/malignancies. It has been reported that MMP9 promotes liver recovery from ischemia and 
reperfusion injury (IRI) by activating TGF-β and suggested that it plays dual roles (bad and good) 
in liver IRI, depending on the stage of the disease (Feng, Wang et al. 2013). Protective roles of 
MMP9 have also been identified in oral cancers depending on the stage of the disease (Vilen, Salo 
et al. 2013). MMP9 displayed protective function in chronic kidney disease (Okada, Kawai et al. 
2012), lung cancer (Gonzalez-Arriaga, Pascual et al. 2012) and systemic autoimmune disease 
(lymphoproliferation and lupus) (Cauwe, Martens et al. 2011). 
We have shown that in colon MMP9 activates Notch1 (Garg, Ravi et al. 2007) whose 
signaling is important for cell fate determination, stem cell potential and lineage commitment and 
importantly in carcinogenesis. Notch1 function is highly context-dependent, and can either be 
oncogenic (van Es, van Gijn et al. 2005) (Korinek, Barker et al. 1997) (El Khatib, Bozko et al. 
2013) or have a tumor suppressor function (Liu, Turkoz et al. 2011) (Devgan, Mammucari et al. 
2005) (Talora, Cialfi et al. 2005) (Banerjee, Hernandez et al. 2015). Different studies have shown 
a link between Notch1 regulation p53 activation, although clear cut association is yet to be 
established (Licciulli, Avila et al. 2013) (Guan, Gong et al. 2013) (Artavanis-Tsakonas, Matsuno 
et al. 1995). Once Notch1 signaling is active by releasing intracellular domain of the Notch 
receptor (NICD), it is then translocated to the nucleus, and forms a complex with transcription 
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factor proteins forming a multiprotein complex, which directly activates transcription of 
downstream genes (Artavanis-Tsakonas, Matsuno et al. 1995, Guan, Gong et al. 2013). We 
hypothesize that Notch1 may mediate tumor suppression by regulating p53 stability.  
Our study therefore establishes the unique role of epithelial derived-MMP9 in CAC as a 
defensive molecule against its conventional role of a mediator of acute inflammation. We have 
also identified that activation of MMP9-Notch1-ARF-p53 axis is responsible for the two plausible 
mechanistic pathways- p53 dependent apoptosis or p21 mediated cell cycle arrest in mediating the 
protective role of epithelial derived-MMP9 and thereby controls or eliminates cells with damaged 
DNA. Outcome of this study highlights the paradox of using MMP9 inhibitors in current therapies 
to treat CAC patients and explains the failure of such treatments in the setting of chronic 
inflammation. Thus, MMP9 can potentially be used in novel therapies in the setting of CAC.  
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3 RESULTS MATRIX METALLOPROTEINASE 9 PLAYS A ROLE IN 
REGULATING GENOMIC INSTABILY BY REDUCING REACTIVE OXYGEN 
SPECIES AND SUPPRESSING DNA DAMAGE VIA MISMATCH REPAIR 
MECHANISM ACTIVATION 
3.1 Introduction 
Inflammatory Bowel Disease (IBD), which includes both Crohn’s Disease (CD) and 
ulcerative colitis (UC), is a chronic inflammatory conditions that affects the gastrointestinal (GI) 
tract as well as the colonic mucosal (Molodecky, Soon et al. 2012). IBD causes epithelial barrier 
disruption by affecting major components of the intestinal GI tract such as epithelial cells, goblet 
cells, immune cells, and intestinal commensal bacterial types (Baumgart and Sandborn 2007, 
Xavier and Podolsky 2007). CD can affect any site where in GI tract from mouth to anus, mostly 
the terminal ileum, and UC occurs predominately at the distal end of the colon (Hanauer and 
Sandborn 2001). These diseases affect approximately 1 to 4 million individuals in the U.S 
(Baumgart and Sandborn 2007). Acute or short-term inflammation is a beneficial response to tissue 
damage and pathogenic challenges. However, unregulated inflammation may lead to chronic and 
malignant cell transformation resulting in cancer(Lynch, Drescher et al. 2014). Thus, individuals 
with chronically active UC have up to a 50% (depending on population cohort) risk of developing 
colitis-associated cancer (CAC) (Rogler 2014). Therefore, The risk of developing CAC increases 
with the length of the disease in correlation with the severity of inflammation.  
Although both sporadic colon cancer (CRC) and CAC are colon cancers, several features 
make CAC distinct from CRC (Walter, Harper et al. 2013). CAC and CRC have different 
molecular events including initiation, promotion and progression during the various stages of 
tumorigenesis (Terzic, Grivennikov et al. 2010). The development of CAC is associated with the 
35 
progressive stages of dysplasia that is significantly different to the pathway of CRC(Waldner and 
Neurath 2015). Unlike CRC that arise from adenomatous polyps(Walter, Harper et al. 2013), CAC 
develops commonly in flat dysplastic tissues in individuals pre-exposed to IBD and polyps are 
mainly localized in the distal colon region (Terzic, Grivennikov et al. 2010, Walter, Harper et al. 
2013).   
In CAC, proinflammatory cytokines consistently secrete ROS which stimulates its 
overproduction within the epithelial cells (Terzic, Grivennikov et al. 2010). The accumulation of 
ROS from chronic inflammation produces DNA damage which accelerates cancer cell growth over 
healthy cells (Lakatos and Lakatos 2008, Erie and Weninger 2014). Increased ROS levels lead to 
DNA damage response (DDR) dysregulation which compromises DNA repair mechanisms 
(Waldner and Neurath 2015). DDR regulates cell proliferation via cell cycle arrest which protects 
against the proliferation of defective DNA (Nardella, Clohessy et al. 2011). Therefore, genomic 
instability from an excess of ROS is directly associated with tumorigenesis (Tian, Gao et al. 2015). 
Matrix Metalloproteinases (MMPs) are zinc-dependent neutral endopeptidases that have 
proteolytic activity against extracellular matrix (ECM) proteins (Sternlicht and Werb 2001, Garg, 
Sarma et al. 2010). Their targets include proteinases, clotting factors, chemotactic molecules, latent 
growth factors, cell surface receptors, and cell-cell adhesion molecules that make them able to 
regulate many biological processes (Cao, Drews et al. 1998, Sternlicht and Werb 2001). MMPs 
are expressed in the GI tract by epithelial cells as well as immune cells (neutrophils, macrophages, 
and lymphocytes) during inflammation (Baugh, Perry et al. 1999, Castaneda, Walia et al. 2005). 
They regulate innate and acquired host defenses by facilitating inflammatory cell recruitment 
across the epithelium and endothelial basement membrane (Ravi, Garg et al. 2007). MMP9, also 
known as 92-kDa type IV collagenase or gelatinase B, plays a key role in ECM degradation and 
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is involved in tissue remodeling (Yabluchanskiy, Ma et al. 2013). It is undetectable in all healthy 
adult tissues but the most predominantly expressed MMP in the GI tract by epithelial cells and 
immune cells in several inflammatory diseases such as IBD, asthma, rheumatoid arthritis, 
nonsteroidal anti-inflammatory drugs (NSAID)-induced gastric ulcers (Bailey, Hembry et al. 
1994, Castaneda, Walia et al. 2005, Walter, Harper et al. 2013).  
We have previously shown that MMP9 knockout animals were more susceptible to CAC 
(Garg, Jeppsson et al. 2011). We have also shown that MMP9 activates p53 via transcription factor 
Notch1 (Garg, Jeppsson et al. 2011, Walter, Harper et al. 2013). Consequently, epithelial not 
neutrophil derived MMP9 could play a protective role in CAC in contrast to its inflammation 
mediator function in acute colitis (Liu, Patel et al. 2013, Walter, Harper et al. 2013, Walter, Pujada 
et al. 2017). Recently, our lab has shown that constitutive expression of MMP9 in the colonic 
epithelium maintains tight junction and mucosal lining integrity in mice during CAC. However, 
the role of MMP9 in the regulation of genomic stability remains unknown. The aim of this study 
is to examine that epithelial derived MMP9 plays a role in genomic stability by DNA damage. In 
this study, we used MMP9 transgenic (TgM9) mice that constitutively expresses MMP9 in the 
colonic epithelium under the villin promoter. As “a proof of principle” model, we evaluated stably 
transfected HCT116 cell lines (expressing wild type p53, a generous gift from Dr. VW Yang, 
Stony Brook University, NY) with and without MMP9 to analyze genomic stability as an in vitro 
model.  
3.2 Methods 
3.2.1 Animal Models 
All animal procedures were performed in accordance with the Guide for the Care of Use 
of Laboratory Animals from the US Public Health Service and with the approval from the Animal 
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Care Committee of Georgia State University. As described previously (Liu, Patel et al. 2013), 
gender matched 8-10 weeks old Transgenic mice with MMP9 overexpression in the colonic 
epithelium (TgM9) and their wild-type (WT) littermates were obtained while crossing the hetz of 
TgM9 of C57/B6 background were used in this study by the start of the experimental protocol. 
Our lab has previously published the extensive characterization of TgM9  (Liu, Patel et al. 2013) 
. The mice were maintained in a 12-hour dark-light cycle and allowed free access to nonpurified 
diet pellets and tap water.  
 
3.2.2 Colitis Associated Cancer Induction 
TgM9 (n=19) and WT (n=21) were separated into two groups in which one group was 
induced with CAC and another group was given water only. The CAC group of TgM9 and WT 
were injected i.p. with 7.6 mg/kg Azoxymethane (AOM, Sigma, St. Louis, MO) on day 0. On day 
7, WT and TgM9 mice were exposed to 3% (w/v) Dextran Sodium Sulfate (DSS, MP Biomedicals, 
Solon, OH), given through drinking water ad libitum for 7 consecutive days. On day 14, their water 
was switched back to regular drinking water. On day 28, their drinking water was again changed 
to 3% DSS for an additional 7-day cycle of DSS exposure. Afterwards, the mice were returned 
back to regular drinking water and sacrificed on day 56. Their colons were opened longitudinally. 
Body weight, stool consistency, and stool occult blood data of all mice were collected during both 
DSS treatment and recovery phase.  
3.2.3 Hematoxylin and Eosin Staining  
The swiss rolls of the colon from both mice groups were fixed in 10%-buffered formalin 
at room temperature and embedded in paraffin. Tissues were sectioned at 6-μm thickness and H&E 
staining was performed. 
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3.2.4 Generation of in vitro models (Cell Culture and Transfection) 
As describe previously stably transfected HCT116 cell lines (expressing wild type p53, a 
generous gift from Dr. VW Yang, Stony Brook University, NY) with and without MMP9 
overexpression were used to analyze genomic instability (O'Sullivan, Gilmer et al. 2015). They 
were transfected for 72 h with a pEGFP plasmid with and without the MMP9 gene in 6 well plate. 
The transfected clones were selected under an antibiotic (Geneticin; GIBCO, Grand Island, NY). 
These transfected clones were screened for MMP9 expression and the three highest MMP9 
expressing clones were selected for HCT116 cell line and were sorted via flow cytometry (BD 
Biosciences). 
3.2.5 Reactive Oxygen Species Assay 
Fresh whole colonic tissues were collected from mice in each group and immediately 
homogenized with cold Phosphate-buffered saline (PBS). Afterwards, the lysates analyzed 
independently using flurescent commercial kit (Cell Biolabs Inc., San Diego, CA) according to 
the manufacturer’s instructions as described previously (Feng, Yan et al. 2016). This kit uses 
Dichlorodihydrofluorescin (DCFH) as a florigenic probe. This probe reacts with ROS species 
and oxidized to fluorescent 2’, 7’-dichlorodihydrofluorescein (DCF). Thus, Fluorescence 
intensity is proportional to the total ROS levels within the sample. The fluorescence was 
analyzed with a fluorometric plate reader at 480/530 nm 
3.2.6 Protein Extraction and Western blot analysis 
As described previously (Garg, Jeppsson et al. 2011), for WB analysis, mucosal stripping 
was obtained from the TgM9 and WT mice with and without CAC induction after the sacrifice. 
The antibodies used were anti-MMP9 (Cell Signaling, Beverly, MA), anti-γH2AX (Abcam), anti-
MLH1 (Abcam), anti-MSH2 (Abcam), anti-PCNA (Abcam), anti-cyclin D1 (Santa Cruz, Dallas, 
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TX), anti-Cyclin A (Cell Signaling), anti-Cyclin E1 (Santa Cruz), anti-γH2AX (Abcam). Goat 
anti-mouse secondary antibody (1:3000; Bio-Rad, Hercules, CA) or goat anti-rabbit secondary 
antibody (1:6000, fAbcam) were used. Densitometry graphs were generated by using image 
acquisition and analysis software by VisionWorksLS Analysis Software (UVP, Upland, CA) 
3.2.7 Immunofluorescence staining 
The colons in each group were fixed in formalin and paraffin-embedded. They were 
washed with 1X PBS (with Tween 20) and then blocked with 3%BSA in 1X PBS for 1 hour at 
37˚C. Next, tissues were stained by phalloidin-Tetramethylrhodamine B isothiocyanate (Sigma-
Aldrich Corp) for 1 hour at room temperature. After washing with 1X PBS (with Tween 20), 
tissues were incubated overnight at 4˚C with anti-γH2AX (Abcam, Cambridge, MA), anti-8OHdG 
(Santa Cruz Biotechnology, Dallas, TX) and anti-SOD1 (Santa Cruz Biotechnology). After 
washing, tissues were incubated with their appropriate FITC secondary antibody for 1 hour at room 
temperature. After washing, the tissues were mounted with ProLong Antifade mounting medium 
(Thermo Fischer Scientific, Waltham, MA) and were analyzed by the fluorescent microscope. 
3.2.8 Statistical analysis 
As described previously (Viennois, Ingersoll et al. 2016), data are presented as means ± 
SE. Groups were compared by Student’s t-test. P values <0.05 was considered statistically 
significant.  
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3.3 Results 
3.3.1 TgM9 mice exhibited lower levels of ROS production in CAC 
 
Figure 10. Constitutive expression of MMP9 in colonic epithelium was associated with 
decreased ROS production in CAC 
(A)Bar graph of ROS levels that were generated and analyzed through DCF-DA from WT and 
TgM9 mice with water and CAC. (B) Immunofluorescence staining of the Swiss rolls from WT 
and TgM9 mice in CAC probed with (B) 8OHdG and (C) SOD1. 
 
TgM9 and their WT littermates were induced with CAC as described in ‘Materials and 
Methods’ section and were sacrificed after 56 days. It is well-documented that elevated levels of 
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ROS due to chronic inflammation produces endogenous DNA damage which accelerates cancer 
cell growth over healthy cells (Mook, Frederiks et al. 2004). Our previous study has established 
epithelial derived-MMP9 as a defensive proteinase in CAC via p53 induced apoptosis causing 
DNA in cells (Walter, Pujada et al. 2017). Thus, we examined if MMP9, being a secretory 
proteinase, plays an important role in the reduction of ROS levels to maintain genomic stability. 
Figure 1A shows a significantly lower ROS levels among TgM9 mice compared to WT mice in 
CAC by using dichlorodihydrofluorescin (DCFH) as a florigenic probe. Next, 
immunofluorescence was performed using two markers of oxidative DNA damage 8OHdG 
(Figure 1B), a modified base that occurs in DNA due to attack by hydroxyl radicals that are 
formed as byproducts and intermediates of aerobic metabolism and during oxidative damage, 
and SOD1 (Figure 1C), a superoxide dismutases responsible for destroying free superoxide 
radicals in the body by converting superoxide radicals to molecular oxygen and hydrogen 
peroxide, were used to validate MMP9 overexpression reduces the amount of ROS in CAC (Sea, 
Sohn et al. 2015). The results show TgM9 mice exhibited less amount of both 8OHdG and SOD1 
ROS markers within the colonic epithelium during CAC. Together, these results indicate that in 
CAC epithelial derived-MMP9 expression is associated with a significantly lower levels of 
ROS/oxidative stress compared to WTs littermates. 
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3.3.2 MMP9 overexpression suppresses the amount of DNA damage in CAC 
 
Figure 11. Constitutive expression of MMP9 in colonic epithelium was associated with 
decreased DNA damage in CAC. 
(A)Immunofluorescence staining of the Swiss rolls from WT and TgM9 mice in CAC probed 
with γH2AX as indicated by white arrows. (B) WB of protein (25 μg/lane) from mucosal 
stripping of TgM9 and WTs with water and CAC was performed and probed with anti-γH2AX. 
The loading control for the blot was GAPDH. Densitometry evaluations of the WB is 
representing by the adjacent bar graph. Each bar represents mean ± S.E., *p< 0.05. Microscopic 
images were taken at 20X magnification. 
  
DNA consistently undergoes oxidative damage by oxygen free radicals which are produced 
inside the cell as a result of ROS production (Sea, Sohn et al. 2015). This causes the formation of 
double-strand breaks (DSBs), which triggers tumorigenesis, which leads to the phosphorylation 
of the histone variant H2AX (γH2AX) (Podhorecka, Skladanowski et al. 2010). Next, we 
investigated the amount of γH2AX in TgM9 mice as compared to its WT littermates. First, we 
performed an immunofluorescent staining using γH2AX to examine the amount of DNA damage 
present within the colon during CAC. The immunofluorescence staining showed a significantly 
higher presence of γH2AX (Figure 12A) as indicated by white arrow within WT compared 
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TgM9 mice during CAC. Next, western blot analysis was done to validate the results of our 
immunofluorescent staining. This also showed a significantly lower amount of γH2AX in TgM9 
mice (12B lanes 4-6) as compared to WT mice (Figure 12B lanes 1-3) within both water and 
CAC conditions. Taken together, our results suggest epithelial-derived MMP9 plays a protective 
role in CAC by reducing the amount of DSBs in the colonic epithelium.  
3.3.3 TgM9 mice exhibited an increase expression of mismatch repair proteins in CAC 
 
Figure 12. TgM9 mice exhibited increased protein expression of MMR proteins MLH1, 
MSH2, and pCNA 
WBs of protein (25/μg/lane) from mucosal stripping of the TgM9 and WTs with CAC were 
performed and probed with (A) anti-MLH1; (B) anti-MSH2 and (C) anti-pCNA.  The loading 
control for each blot was GAPDH. Each blot was a representation of three individual 
experiments. Bar graphs are the representation of densitometry evaluations of the western blots. 
Each bar represents mean ± S.E., *p< 0.05. 
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 ROS downregulates MMR proteins by NO-induce upregulation of DNA 
methyltransferase which results in cytosine base methylation of MLH1 as well as silencing the 
promoter and loss of gene expression at the protein level and displacing the MSH2/MSH6 
dimerization (Bridge, Rashid et al. 2014). In CAC, MMP9 may play a significant role in 
reducing genomic instability by potentially regulating MMR genes (Garg, Sarma et al. 2010). 
Thus, our next step was to examine the protein expression of MMR proteins with and without 
MMP9 overexpression in the colonic epithelium in both basal and CAC conditions. The western 
blot analysis of mismatch repair associated proteins (MMR) showed a significant increase of 
MLH1 (Figure 13A lanes 4-6) and pCNA (Figure 13C lanes 4-6) in TgM9 mice during CAC 
compared to WT mice (Figure 13A lanes 1-3 and Figure 13C). Also, Figure 13B showed that 
TgM9 mice had an increase of MSH2 expression (lanes 4-6) as compared to WT mice (lanes 1-
3). Each blot was normalized for loading by immunoblotting with housekeeping genes GAPDH. 
Taken together, our results indicate epithelial derived MMP9 expression promotes the activation 
of MMR genes which could play a role in the reducing of DNA damage during CAC.  
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3.3.4 Overexpression of MMP9 in human colon carcinoma cell line HCT116 displayed 
decreased expression of γH2AX and MDC1 and increased expression of MLH1 
 
Figure 13. Overexpression MMP9 in human colon carcinoma cell line HCT116 showed 
decreased DNA damage and increased MMR protein expression. 
WB of protein (25/μg/lane) from whole cell lysate of stably transfected HCT116 cells with or 
without MMP9 were performed and probed with; (A) anti-γH2AX; (B) anti-MDC1; (C) anti-
MLH1; and (D) anti-MSH2. The loading control for each blot was GAPDH. Each blot was a 
representation of three individual experiments. Bar graphs are the representation of densitometry 
evaluations of the western blots. Each bar represents mean ± S.E., *p< 0.05. 
   
The DNA damage response (DDR) is initiated to restore genomic stability from ROS lead 
mutations. Furthermore, MMR gene are inactivated at the protein level from ROS oxidation 
during inflammation based carcinogenesis (Colotta, Allavena et al. 2009, Terzic, Grivennikov et 
al. 2010). Alternatively, to support our hypothesis that MMP9 reduces DNA damage, we used 
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stably transfected colon carcinoma human cell line HCT116 with (vector) and without MMP9 
expression. Figure 3A and 3B show a decrease of DNA damage marker γH2AX and its adaptor 
protein MDC1 in MMP9 overexpressing cells (lanes 4-6) as compared to vector (lanes 1-3) 
respectively. We also observed a significant increase of mismatch repair gene MLH1 in MMP9 
overexpressing cells (Figure 3C lanes 4-6) than the vector (Figure 3C lanes 1-3). However, 
Figure 3D shows no significant difference of protein expression of another mismatch repair 
protein MSH2 between MMP9 overexpressing cells. Taken together, both in vivo and in vitro 
data supports epithelial derived MMP9 expression plays an indispensable role in reducing of 
DNA damage as well as in activating MMR machinery in CAC.  
3.4 Conclusion 
The risk of individuals developing CAC with IBD is generally attributed to UC patients as opposed 
to individuals suffering from CD (Morson 1966, Nieminen, Jussila et al. 2014). It is reported that 
individuals with UC have a 2.4-fold increased risk of developing CAC 15 years after acquiring the 
disease (Jess, Rungoe et al. 2012). The development of CAC is referred to as the inflammation-
dysplasia-carcinoma pathway in which low to high grade dysplasia in intestinal inflammation 
leads to subsequent invasive carcinoma (Zisman and Rubin 2008). Thus, the physiological and 
pathological CAC progression leads to difficulty in the development of therapeutic strategies.  
Chronic inflammation in response to an infection or tissue damage eliminates dead cells 
and promotes tissue restoration by activation of stem and myofibroblast cells, cell proliferation, 
angiogenesis. However, an excess oxidative stress is a key component of chronic inflammation 
from innate immune cells that release various ROS into the tissue microenvironment upon 
activation(Waldner and Neurath 2015). Oxidative damage such as DNA sequence 
rearrangement, DNA lesions, and activation of oncogenes that play a key role in the initiation 
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and progression of tumorigenesis (Waris and Ahsan 2006). These mutations in DNA from ROS 
include oxidized nucleotides, alkali labile sites, single and double strand breaks (Jaruga, 
Theruvathu et al. 2004). Guanine to Thymine transversion are the most frequent mutations in the 
p53 tumor suppressor which is the first mutation in CAC (Hollstein, Sidransky et al. 1991). Also, 
8OHdG, an oxidative stress-depend base modification, is often found in dysplastic tissue as well 
as increased concentrations of nitric oxide in IBD tissue (Waldner and Neurath 2015).  
Matrix metalloproteinases (MMPs) have known as key mediators of the extracellular 
matrix (ECM) which promotes and restricts ECM assembly, structure, and quantity  (Weber and 
Saftig 2012, Apte and Parks 2015, Kessenbrock, Wang et al. 2015). Among the 25 known MMPs, 
MMP9 is unique as it is undetectable in healthy adult tissues but highly expressed in various 
inflammatory diseases such as asthma, rheumatoid arthritis and nonsteroidal anti-inflammatory 
drugs (NSAID)-induced gastric ulcers (Bailey, Hembry et al. 1994, Baugh, Evans et al. 1998, Ravi, 
Garg et al. 2007). Distinctly, MMP9 has three type II fibronectin repeats, containing an elongated 
linker between catalytic and hemopexin like domain. This domain is essential in binding to 
denatured collagen or gelatin (Opdenakker, Van den Steen et al. 2001). Our lab has shown that 
epithelial not neutrophil-derived MMP9 mediates tissue damage during intestinal inflammation 
and inhibits epithelial cell adhesion, which is required for epithelial cells to migrate and attaches 
to appropriate matrix after damage (Castaneda, Walia et al. 2005).  However, our lab has also 
reported the tumor suppressor role of epithelial based MMP9 by activating p53, which mediates 
cell-cycle arrest and apoptosis, via Notch 1 signaling in CAC (Walter, Harper et al. 2013, Walter, 
Pujada et al. 2017). We have also shown that MMP9-/- mice exhibited lower amount of apoptosis 
with significantly more cell proliferation (Garg, Sarma et al. 2010).  Our previous studies of 
inhibiting Notch1 signaling using difluorophenacetly-L-alanly-S-phenylglycine t-butyl ester 
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(DAPT) as a pharmacological blocker displayed decrease protein expressions of p53, p21, and 
activated caspase-3 in WT mice further validated our research findings (Garg, Jeppsson et al. 
2011). MMP9 is secreted by both epithelial and immune cells in various tissues during 
inflammation. Recently, our lab has shown epithelial derived MMP9 also preserves the epithelial 
barrier and sustains the mucosal lining of the colonic epithelium in CAC (ADANI paper). Thus, it 
is important to understand the effects of epithelial derived MMP9 being a tumor suppressor in 
CAC.  
In this study, we used TgM9 mice that constitutively express MMP9 in the colonic 
epithelium (Liu, Patel et al. 2013), to examine the role of epithelial derived MMP9 in maintaining 
genomic stability during CAC. We observed a significantly decreased amount of ROS in mice that 
exhibited constitutive expression of MMP9 in the colonic epithelium compared to their wildtype 
littermates. We have also shown less genomic instability from CAC in TgM9 by a significant 
decrease in DNA damage as well as activation of Mismatch Repair mechanisms compared to WTs. 
Our in vivo model demonstrated lower levels of ROS in TgM9 mice using the florigenic probe 
dichlorodihydrofluorescin (DCFH) as well as lesser amounts of ROS damage markers 8OHdG and 
SOD1 present in the colonic epithelium compared to their WT littermates. The TgM9 also 
displayed a significant decrease in protein levels of γH2AX and an increased protein expression 
of mismatch repair mechanisms as opposed to their WT littermates. Our in vitro model of human 
colonic carcinoma cell line HCT116 stably transfected with MMP9 shows a decrease of γH2AX 
and its adaptor protein MDC1 as well as an increase of MLH1 as compared to vector which 
supports the in vivo data of decreased DNA damage and MMR activation. Taken together, these 
results show epithelial derived MMP9 maintains genomic stability during CAC. Our in vivo and 
in vitro data showed direct correlation MMP9 expression and γH2AX reduction and MLH1 
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activation indicating mechanisms MMP9 promotes genomic stability by DNA damage reduction 
and MMR activation. Overall, the data suggest that epithelial derived-MMP9 maintains genomic 
stability minimizes the amount of ROS in the colonic epithelium which reduces the amount of 
DNA damage and allows for the activation of MMR mechanisms in CAC.  
The DNA damage response (DDR) is activated to repair RONS-induced mutations which 
comprises genomic integrity. It regulates cellular proliferation from cell senescence activation, an 
irreversible cell cycle arrest which provides protection against defective DNA amplification and 
mutation (Nardella, Clohessy et al. 2011). Also, inflammation induced carcinogenesis leads to 
MMR gene repression allowing for ROS to oxidize the inactivated mismatch repair genes at the 
protein level (Colotta, Allavena et al. 2009, Terzic, Grivennikov et al. 2010). For instance, MLH1 
expression is inhibited in enterocytes via histone deacetylase and epigenetic repression of the Mlh1 
promoter via DEC-1 mediation within Giα2-/- mice which spontaneously develop inflammation 
and cancer in the colon (Edwards, Witherspoon et al. 2009). Genetic mutations of MLH1 are also 
found within patients suffering from Lynch syndrome, which is a hereditary non-polyposis colon 
cancer (HNPPC) (Heinen 2014). These mutations have been identified in roughly 50% of 
individuals with Lynch syndrome (Heinen 2014). Our data suggest MMP9 expression plays a role 
in genomic stability within the colonic epithelium which represses the oxidation of MLH1 from 
ROS during CAC. 
Our study focuses on the novel role of epithelial derived-MMP9 in CAC as playing a 
protective role instead of its conventional role as a mediator or acute inflammation.  We have 
established that epithelial derived MMP9 expression plays a role in maintaining genomic stability 
in CAC by reducing the amount of ROS, DNA damage, and the potential regulation of MMR 
genes. Furthermore, our study highlights the shortcomings of MMP9 inhibitors in recently used 
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therapies to treat CAC patients. Thus, our proposal of the protective role of MMP9 in CAC will 
be able to extend research to the clinical practice by establishing the inhibition of MMP9 should 
be avoided in chronic inflammatory conditions.   Also, this study underlines the importance of 
avoiding humanized versions of MMP9 inhibitors or neutralizing antibodies for CAC patients.  
Understanding this defensive role of MMP9 in CAC is an important way to improve human 
healthcare costs as being a helpful proteinase.  
4 CONCLUSIONS 
 
Figure 14. Schematic Overview of Epithelial derived MMP9 plays a protective role during 
CAC 
 
Inflammatory bowel diseases (IBDs) are incurable, chronic inflammatory conditions of 
the gut and disproportionately affect highly industrialized regions such as North America and 
Europe, making them a growing, worldwide concern (Molodecky, Soon et al. 2012). It is well-
known that chronic inflammation predisposes tissues to oncogenic mutations in its constituent 
cells, and in the gut this manifests as CAC. My lab has shown MMP9 is highly expressed in 
51 
chronic inflammation and MMP-9-/- models to have increased susceptibility to CAC (Garg, 
Sarma et al. 2010). Understanding this role of MMP9 will assist in the drive for treatments to 
prevent carcinogenesis in chronically inflamed tissues. My overall hypothesis is that epithelial 
derived MMP9 mediates tumor suppression in CAC via activation of Notch1 and regulating 
genomic stability. Thus, our hypothesis was tested with two aims, which could 1) significantly 
impact future efforts to target key cells or gene pathways important to treat CAC 
development/severity, and 2) bring an unprecedented specificity of treatment to cancer 
prevention in IBD patients.  
In CAC, p53 is the first oncogenes to be mutated (Ullman and Itzkowitz 2011).  Wildtype 
p53 plays an important role of tumor suppressor in regulating cancer progression. In normal cells 
ARF (alternative reading frame, termed p19ARF in mouse cells and p14ARF in human cells and an 
upstream regulator of p53), binds with active Mdm2 molecules, resulting in increased levels of 
non-mutated p53. In the absence of ARF protein, Mdm2 binds with non-mutated p53 and 
degrades it by ubiquitination (Zindy, Williams et al. 2003). Hence suppression of ARF function 
by oncogenic signaling pathways favors tumor formation. The activation of non-mutated p53 
modulates tumor suppression by initiating a transcriptional program that results in regulating 
apoptosis or promoting cell cycle arrest or senescence. Thus, we investigated the tumor 
suppressive role of epithelial derived-MMP9 by identifying a novel mechanistic pathway 
“MMP9-ARF-p53 axis” via Notch1 activation in CAC. Our results showed thickening of the 
mucosal layer due to inflammation and number of polyps were significantly lesser among TgM9 
mice compared to WTs in CAC. Also, TgM9 displayed slightly fewer dysplastic lesions as 
compared to their WT littermates in CAC. Thus, the results indicate that villin-MMP9 mice 
express functional MMP9 in the colonic mucosa which was more protected against neutrophil 
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infiltration and tumorigenesis in CAC compared to WT littermates which is the same as CAC 
patients. Furthermore, western blot analysis to show an increased expression of activated Notch1 
and p53 within TgM9 vs. WT mice. In response to oncogene activation, p14ARF can activate p53 
expression and is a key negative regulator of the E3 ubiquitin ligase, MDM2, that targets p53 
acetylation(Reisman and Loging 1998).  
We have also shown an increase in apoptosis in TgM9 mice with CAC as the two 
regulatory cellular functions to remove damaged or abnormal cell as well as a significant amount 
of cell cycle arrest with HCT116 cells overexpressing MMP9 as it is predicted to so during CAC. 
The bimolecular complexes of CDK and their Cyclin partners send the signals to responder 
molecules, such as p21WAF1/Cip1, to move through cell growth and division (Harper, Adami et al. 
1993).  Among the cell cycle regulatory proteins activated following cellular stress signals, we 
have shown p21WAF1/Cip1, which is a downstream target of p53, was increased during the 
overexpression of MMP9 in CAC which is a Cyclin-dependent kinase (CDK) inhibitor that plays 
a significant role in maintaining cellular integrity. There was also increased expression of 
Cyclins A and E during MMP9 overexpression as well as cell cycle arrest occurring in the S 
phase in HCT116 cells overexpressing MMP9. These results together should outline an 
underlying molecular mechanism of the protective role of epithelial-derived MMP9 by mediating 
cell cycle arrest and apoptosis in CAC. Thus, epithelial derived MMP9 has a defensive role in 
inflammation-associated cancer colorectal cancer by activating the MMP9-ARF-p53 axis. 
It is well-documented that an excess of reactive oxygen species and nitrogen compounds 
(RNOS) from chronic inflammation produces endogenous DNA damage which accelerates 
cancer cell growth over healthy cells (Mook, Frederiks et al. 2004). Therefore, genomic 
instability is directly associated with tumorigenesis (Tian, Gao et al. 2015). MMP9 being a 
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secretory proteinase may play an important role in the down-regulation of genomic instability. 
Thus, I examined if MMP9 plays a defensive role from genotoxicity by detecting endogenous 
levels of initial DNA repair sensors (γH2AX) and regulation of initial mismatch repair genes in 
CAC. The immunofluorescent staining results will reveal TgM9 CAC mice to have a decrease in 
γH2AX expression as opposed to the WT CAC mice. Western blot analysis confirmed an 
increased expression of the initial DNA damage repair (DDR) sensor γH2AX and MDC1 (its 
adaptor protein) within WT CAC mice as opposed to TgM9 CAC mice. These results were 
support by using γ-radiated HCT116 and MEF models to support the in vivo outcomes. These 
results indicated that MMP9 protects from genotoxicity by decreased endogenous levels of 
γH2AX in CAC. 
The DNA mismatch repair (MMR) pathway and human cancer are been linked together 
since MSH2 mutations were discovering in patients with hereditary non-polyposis colon cancer 
(Fishel, Lescoe et al. 1993, Heinen 2014). MMP9 may also play important role in down 
regulation of genomic instability by potentially regulating MMR genes in CAC (Garg, Sarma et 
al. 2010). Thus, I investigated the role of MMP9 in suppressing DNA damage due to activation 
of MMR genes. Western blot analysis exhibited an increase of MLH1, MSH2, and pCNA 
outcomes in TgM9 mice as compared to WT mice during CAC. MMP9 decreases DNA damage 
by increasing expression of MMR genes during CAC. In vitro models mentioned above were 
used to support by the in vivo data.  Taken together, these results indicate that overexpression of 
MMP9 will play a defensive role in CAC by reducing ROS and activating the MMR pathway. 
Thus, epithelial derived MMP9 mediates tumor suppression via activation of Notch1 and 
regulating genomic stability in Colitis Associated Cancer (CAC).  
 
54 
REFERENCES 
A, D. I. C. (2013). "Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix 
metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients 
with kidney tumors." Oncology letters 5(5): 1677-1681. 
  
Al-Dasooqi, N., et al. (2009). "Matrix metalloproteinases: key regulators in the pathogenesis of 
chemotherapy-induced mucositis?" Cancer chemotherapy and pharmacology 64(1): 1-9. 
  
Alexander, J. S. and J. W. Elrod (2002). "Extracellular matrix, junctional integrity and matrix 
metalloproteinase interactions in endothelial permeability regulation." Journal of anatomy 
200(6): 561-574. 
  
Apte, S. S. and W. C. Parks (2015). "Metalloproteinases: A parade of functions in matrix biology 
and an outlook for the future." Matrix biology : journal of the International Society for Matrix 
Biology 44-46: 1-6. 
  
Artavanis-Tsakonas, S., et al. (1995). "Notch signaling." Science 268(5208): 225-232. 
  
Atsumi, Y., et al. (2013). "The Arf/p53 protein module, which induces apoptosis, down-regulates 
histone H2AX to allow normal cells to survive in the presence of anti-cancer drugs." J Biol 
Chem 288(19): 13269-13277. 
  
Bailey, C. J., et al. (1994). "Distribution of the matrix metalloproteinases stromelysin, gelatinases 
A and B, and collagenase in Crohn's disease and normal intestine." Journal of clinical pathology 
47(2): 113-116. 
  
Banerjee, D., et al. (2015). "Notch suppresses angiogenesis and progression of hepatic 
metastases." Cancer Res 75(8): 1592-1602. 
  
Baugh, M. D., et al. (1998). "Expression of matrix metalloproteases in inflammatory bowel 
disease." Annals of the New York Academy of Sciences 859: 249-253. 
  
Baugh, M. D., et al. (1999). "Matrix metalloproteinase levels are elevated in inflammatory bowel 
disease." Gastroenterology 117(4): 814-822. 
  
Baumgart, D. C. and W. J. Sandborn (2007). "Inflammatory bowel disease: clinical aspects and 
established and evolving therapies." Lancet 369(9573): 1641-1657. 
  
Bini, A., et al. (1996). "Degradation of cross-linked fibrin by matrix metalloproteinase 3 
(stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond." Biochemistry 35(40): 
13056-13063. 
  
Bjorklund, M. and E. Koivunen (2005). "Gelatinase-mediated migration and invasion of cancer 
cells." Biochim Biophys Acta 1755(1): 37-69. 
  
Commented [WU5]: You must have a reference, works cited, or 
bibliography section with at least two entries before I can approve 
your document.  
55 
Bond, M., et al. (2001). "Inhibition of transcription factor NF-kappaB reduces matrix 
metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells." Cardiovascular 
research 50(3): 556-565. 
  
Bridge, G., et al. (2014). "DNA mismatch repair and oxidative DNA damage: implications for 
cancer biology and treatment." Cancers 6(3): 1597-1614. 
  
Burg-Roderfeld, M., et al. (2007). "MMP-9-hemopexin domain hampers adhesion and migration 
of colorectal cancer cells." Int J Oncol 30(4): 985-992. 
  
Canepa, E. T., et al. (2007). "INK4 proteins, a family of mammalian CDK inhibitors with novel 
biological functions." IUBMB life 59(7): 419-426. 
  
Cao, J., et al. (1998). "The propeptide domain of membrane type 1 matrix metalloproteinase is 
required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase 
A." The Journal of biological chemistry 273(52): 34745-34752. 
  
Castaneda, F. E., et al. (2005). "Targeted deletion of metalloproteinase 9 attenuates experimental 
colitis in mice: central role of epithelial-derived MMP." Gastroenterology 129(6): 1991-2008. 
  
Cauwe, B., et al. (2011). "Deficiency of gelatinase B/MMP-9 aggravates lpr-induced 
lymphoproliferation and lupus-like systemic autoimmune disease." Journal of autoimmunity 
36(3-4): 239-252. 
  
Chang, W. C., et al. (2007). "Loss of p53 enhances the induction of colitis-associated neoplasia 
by dextran sulfate sodium." Carcinogenesis 28(11): 2375-2381. 
  
Chen, L. F. and W. C. Greene (2004). "Shaping the nuclear action of NF-kappaB." Nature 
reviews. Molecular cell biology 5(5): 392-401. 
  
Choi, P. M. and M. P. Zelig (1994). "Similarity of colorectal cancer in Crohn's disease and 
ulcerative colitis: implications for carcinogenesis and prevention." Gut 35(7): 950-954. 
  
Colotta, F., et al. (2009). "Cancer-related inflammation, the seventh hallmark of cancer: links to 
genetic instability." Carcinogenesis 30(7): 1073-1081. 
  
Cooks, T., et al. (2014). "Caught in the cross fire: p53 in inflammation." Carcinogenesis 35(8): 
1680-1690. 
  
Cooper, H. S., et al. (2000). "Dysplasia and cancer in the dextran sulfate sodium mouse colitis 
model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-
catenin and p53 expression and the role of inflammation." Carcinogenesis 21(4): 757-768. 
  
Cooper, H. S., et al. (1993). "Clinicopathologic study of dextran sulfate sodium experimental 
murine colitis." Lab Invest 69(2): 238-249. 
  
56 
Cornelius, L. A., et al. (1998). "Matrix metalloproteinases generate angiostatin: effects on 
neovascularization." Journal of immunology 161(12): 6845-6852. 
  
Curci, J. A., et al. (1998). "Expression and localization of macrophage elastase (matrix 
metalloproteinase-12) in abdominal aortic aneurysms." The Journal of clinical investigation 
102(11): 1900-1910. 
  
Devgan, V., et al. (2005). "p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 
expression downstream of Notch1 activation." Genes Dev 19(12): 1485-1495. 
  
Donehower, L. A. (1996). "The p53-deficient mouse: a model for basic and applied cancer 
studies." Seminars in cancer biology 7(5): 269-278. 
  
Edwards, R. A., et al. (2009). "Epigenetic repression of DNA mismatch repair by inflammation 
and hypoxia in inflammatory bowel disease-associated colorectal cancer." Cancer research 
69(16): 6423-6429. 
  
Egeblad, M. and Z. Werb (2002). "New functions for the matrix metalloproteinases in cancer 
progression." Nature reviews. Cancer 2(3): 161-174. 
  
El Khatib, M., et al. (2013). "Activation of Notch signaling is required for cholangiocarcinoma 
progression and is enhanced by inactivation of p53 in vivo." PLoS One 8(10): e77433. 
  
Erie, D. A. and K. R. Weninger (2014). "Single molecule studies of DNA mismatch repair." 
DNA repair 20: 71-81. 
  
Feng, J., et al. (2016). "Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes 
Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway." BioMed 
research international 2016: 1450843. 
  
Feng, M., et al. (2013). "Matrix metalloprotease 9 promotes liver recovery from ischemia and 
reperfusion injury." The Journal of surgical research 180(1): 156-161. 
  
Fiocchi, C. (1998). "Inflammatory bowel disease: etiology and pathogenesis." Gastroenterology 
115(1): 182-205. 
  
Fishel, R., et al. (1993). "The human mutator gene homolog MSH2 and its association with 
hereditary nonpolyposis colon cancer." Cell 75(5): 1027-1038. 
  
Fukata, M. and M. T. Abreu (2008). "Role of Toll-like receptors in gastrointestinal 
malignancies." Oncogene 27(2): 234-243. 
  
Garg, P., et al. (2011). "Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-
associated cancer in mice." Gastroenterology 141(4): 1381-1392. 
  
57 
Garg, P., et al. (2007). "Matrix metalloproteinase-9 regulates MUC-2 expression through its 
effect on goblet cell differentiation." Gastroenterology 132(5): 1877-1889. 
  
Garg, P., et al. (2010). "Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-
associated cancer." Cancer Res 70(2): 792-801. 
  
Garg, P., et al. (2009). "Matrix metalloproteinase-9-mediated tissue injury overrides the 
protective effect of matrix metalloproteinase-2 during colitis." Am J Physiol Gastrointest Liver 
Physiol 296(2): G175-184. 
  
Giannandrea, M. and W. C. Parks (2014). "Diverse functions of matrix metalloproteinases during 
fibrosis." Disease models & mechanisms 7(2): 193-203. 
  
Gonzalez-Arriaga, P., et al. (2012). "Genetic polymorphisms in MMP 2, 9 and 3 genes modify 
lung cancer risk and survival." BMC cancer 12: 121. 
  
Grana, X. and E. P. Reddy (1995). "Cell cycle control in mammalian cells: role of cyclins, cyclin 
dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors 
(CKIs)." Oncogene 11(2): 211-219. 
  
Guan, A., et al. (2013). "Regulation of p53 by jagged1 contributes to angiotensin II-induced 
impairment of myocardial angiogenesis." PLoS One 8(10): e76529. 
  
Hald, A., et al. (2011). "MMP9 is protective against lethal inflammatory mass lesions in the 
mouse colon." Disease models & mechanisms 4(2): 212-227. 
  
Hanauer, S. B. and W. Sandborn (2001). "Management of Crohn's disease in adults." The 
American journal of gastroenterology 96(3): 635-643. 
  
Harper, J. W., et al. (1993). "The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 
cyclin-dependent kinases." Cell 75(4): 805-816. 
  
He, B. J., et al. (2011). "Oxidation of CaMKII determines the cardiotoxic effects of aldosterone." 
Nature medicine 17(12): 1610-1618. 
  
Heinen, C. D. (2014). "Translating mismatch repair mechanism into cancer care." Current drug 
targets 15(1): 53-64. 
  
Hollstein, M., et al. (1991). "p53 mutations in human cancers." Science 253(5015): 49-53. 
  
Itzkowitz, S. H. (2006). "Molecular biology of dysplasia and cancer in inflammatory bowel 
disease." Gastroenterology clinics of North America 35(3): 553-571. 
  
Jaruga, P., et al. (2004). "Complete release of (5'S)-8,5'-cyclo-2'-deoxyadenosine from 
dinucleotides, oligodeoxynucleotides and DNA, and direct comparison of its levels in cellular 
DNA with other oxidatively induced DNA lesions." Nucleic acids research 32(11): e87. 
58 
  
Jess, T., et al. (2012). "Risk of colorectal cancer in patients with ulcerative colitis: a meta-
analysis of population-based cohort studies." Clinical gastroenterology and hepatology : the 
official clinical practice journal of the American Gastroenterological Association 10(6): 639-645. 
  
John, P. C., et al. (2001). "Cyclin/Cdk complexes: their involvement in cell cycle progression 
and mitotic division." Protoplasma 216(3-4): 119-142. 
  
Jonsson, S., et al. (2011). "Increased levels of leukocyte-derived MMP-9 in patients with stable 
angina pectoris." PloS one 6(4): e19340. 
  
Kanellou, P., et al. (2008). "Genomic instability, mutations and expression analysis of the tumour 
suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis." Cancer 
letters 264(1): 145-161. 
  
Kessenbrock, K., et al. (2015). "Matrix metalloproteinases in stem cell regulation and cancer." 
Matrix biology : journal of the International Society for Matrix Biology 44-46: 184-190. 
  
Khan, S., et al. (2004). "p14ARF is a component of the p53 response following ionizing 
irradiation of normal human fibroblasts." Oncogene 23(36): 6040-6046. 
  
Korinek, V., et al. (1997). "Constitutive transcriptional activation by a beta-catenin-Tcf complex 
in APC-/- colon carcinoma." Science 275(5307): 1784-1787. 
  
Kraus, S. and N. Arber (2009). "Inflammation and colorectal cancer." Current opinion in 
pharmacology 9(4): 405-410. 
  
Lakatos, P. L. and L. Lakatos (2008). "Risk for colorectal cancer in ulcerative colitis: changes, 
causes and management strategies." World journal of gastroenterology : WJG 14(25): 3937-
3947. 
  
Landskron, G., et al. (2014). "Chronic Inflammation and Cytokines in the Tumor 
Microenvironment." Journal of immunology research 2014: 149185. 
  
Leroy, B., et al. (2014). "TP53 mutations in human cancer: database reassessment and prospects 
for the next decade." Human mutation 35(6): 672-688. 
  
Licciulli, S., et al. (2013). "Notch1 is required for Kras-induced lung adenocarcinoma and 
controls tumor cell survival via p53." Cancer Res 73(19): 5974-5984. 
  
Liu, H., et al. (2013). "Constitutive expression of MMP9 in intestinal epithelium worsens murine 
acute colitis and is associated with increased levels of proinflammatory cytokine Kc." American 
journal of physiology. Gastrointestinal and liver physiology 304(9): G793-803. 
  
59 
Liu, H., et al. (2013). "Constitutive expression of MMP9 in intestinal epithelium worsens murine 
acute colitis and is associated with increased levels of proinflammatory cytokine Kc." Am J 
Physiol Gastrointest Liver Physiol 304(9): G793-803. 
  
Liu, Z., et al. (2011). "Notch1 loss of heterozygosity causes vascular tumors and lethal 
hemorrhage in mice." J Clin Invest 121(2): 800-808. 
  
Llano, E., et al. (1999). "Identification and characterization of human MT5-MMP, a new 
membrane-bound activator of progelatinase a overexpressed in brain tumors." Cancer research 
59(11): 2570-2576. 
  
Lopez-Otin, C. and J. S. Bond (2008). "Proteases: multifunctional enzymes in life and disease." J 
Biol Chem 283(45): 30433-30437. 
  
Lubbe, W. J., et al. (2006). "Tumor epithelial cell matrix metalloproteinase 9 is a target for 
antimetastatic therapy in colorectal cancer." Clin Cancer Res 12(6): 1876-1882. 
  
Lynch, H. T., et al. (2014). "Genetics, biomarkers, hereditary cancer syndrome diagnosis, 
heterogeneity and treatment: a review." Current treatment options in oncology 15(3): 429-442. 
  
Mah, L. J., et al. (2010). "GammaH2AX as a molecular marker of aging and disease." 
Epigenetics 5(2): 129-136. 
  
Mamay, C. L., et al. (2001). "Cyclin D1 as a proliferative marker regulating retinoblastoma 
phosphorylation in mouse lung epithelial cells." Cancer Lett 168(2): 165-172. 
  
Martelli, F., et al. (2001). "p19ARF targets certain E2F species for degradation." Proc Natl Acad 
Sci U S A 98(8): 4455-4460. 
  
Matsubara, M., et al. (1991). "Mechanism of basement membrane dissolution preceding corneal 
ulceration." Investigative ophthalmology & visual science 32(13): 3221-3237. 
  
Matsubara, M., et al. (1991). "Mechanism of basement membrane dissolution preceding corneal 
ulceration." Invest Ophthalmol Vis Sci 32(13): 3221-3237. 
  
Mohan, R., et al. (2002). "Matrix metalloproteinase gelatinase B (MMP-9) coordinates and 
effects epithelial regeneration." The Journal of biological chemistry 277(3): 2065-2072. 
  
Molodecky, N. A., et al. (2012). "Increasing incidence and prevalence of the inflammatory bowel 
diseases with time, based on systematic review." Gastroenterology 142(1): 46-54 e42; quiz e30. 
  
Mook, O. R., et al. (2004). "The role of gelatinases in colorectal cancer progression and 
metastasis." Biochimica et biophysica acta 1705(2): 69-89. 
  
Mook, O. R., et al. (2004). "The role of gelatinases in colorectal cancer progression and 
metastasis." Biochim Biophys Acta 1705(2): 69-89. 
60 
  
Morson, B. C. (1966). "Cancer in ulcerative colitis." Gut 7(5): 425-426. 
  
Nardella, C., et al. (2011). "Pro-senescence therapy for cancer treatment." Nature reviews. 
Cancer 11(7): 503-511. 
  
Newell, K. J., et al. (2002). "Matrilysin (matrix metalloproteinase-7) expression in ulcerative 
colitis-related tumorigenesis." Mol Carcinog 34(2): 59-63. 
  
Nieminen, U., et al. (2014). "Inflammation and disease duration have a cumulative effect on the 
risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry 
data." International journal of cancer 134(1): 189-196. 
  
O'Farrell, T. J. and T. Pourmotabbed (1998). "The fibronectin-like domain is required for the 
type V and XI collagenolytic activity of gelatinase B." Archives of biochemistry and biophysics 
354(1): 24-30. 
  
O'Sullivan, S., et al. (2015). "Matrix metalloproteinases in inflammatory bowel disease: an 
update." Mediators of inflammation 2015: 964131. 
  
Ohta, Y. and K. Ichimura (2000). "Proliferation markers, proliferating cell nuclear antigen, Ki67, 
5-bromo-2'-deoxyuridine, and cyclin D1 in mouse olfactory epithelium." Ann Otol Rhinol 
Laryngol 109(11): 1046-1048. 
  
Okada, R., et al. (2012). "Matrix metalloproteinase-9 gene polymorphisms and chronic kidney 
disease." American journal of nephrology 36(5): 444-450. 
  
Okamoto, R. and M. Watanabe (2005). "Cellular and molecular mechanisms of the epithelial 
repair in IBD." Digestive diseases and sciences 50 Suppl 1: S34-38. 
  
Okamoto, T., et al. (2001). "Activation of matrix metalloproteinases by peroxynitrite-induced 
protein S-glutathiolation via disulfide S-oxide formation." The Journal of biological chemistry 
276(31): 29596-29602. 
  
Opdenakker, G., et al. (2001). "Gelatinase B: a tuner and amplifier of immune functions." Trends 
in immunology 22(10): 571-579. 
  
Pacheco, M. M., et al. (1998). "Expression of gelatinases A and B, stromelysin-3 and matrilysin 
genes in breast carcinomas: clinico-pathological correlations." Clin Exp Metastasis 16(7): 577-
585. 
  
Papon, J. F., et al. (2006). "Matrix metalloproteinase-2 and -9 expression in sinonasal inverted 
papilloma." Rhinology 44(3): 211-215. 
  
Podhorecka, M., et al. (2010). "H2AX Phosphorylation: Its Role in DNA Damage Response and 
Cancer Therapy." Journal of nucleic acids 2010. 
61 
  
Pozzi, A., et al. (2002). "Low plasma levels of matrix metalloproteinase 9 permit increased 
tumor angiogenesis." Oncogene 21(2): 272-281. 
  
Ravi, A., et al. (2007). "Matrix metalloproteinases in inflammatory bowel disease: boon or a 
bane?" Inflammatory bowel diseases 13(1): 97-107. 
  
Reisman, D. and W. T. Loging (1998). "Transcriptional regulation of the p53 tumor suppressor 
gene." Seminars in cancer biology 8(5): 317-324. 
  
Rogler, G. (2014). "Chronic ulcerative colitis and colorectal cancer." Cancer letters 345(2): 235-
241. 
  
Rowsell, S., et al. (2002). "Crystal structure of human MMP9 in complex with a reverse 
hydroxamate inhibitor." Journal of molecular biology 319(1): 173-181. 
  
Scully, R. and A. Xie (2013). "Double strand break repair functions of histone H2AX." Mutat 
Res 750(1-2): 5-14. 
  
Sea, K., et al. (2015). "Insights into the role of the unusual disulfide bond in copper-zinc 
superoxide dismutase." The Journal of biological chemistry 290(4): 2405-2418. 
  
Sedelnikova, O. A. and W. M. Bonner (2006). "GammaH2AX in cancer cells: a potential 
biomarker for cancer diagnostics, prediction and recurrence." Cell cycle 5(24): 2909-2913. 
  
Sharpless, N. E. and R. A. DePinho (1999). "The INK4A/ARF locus and its two gene products." 
Curr Opin Genet Dev 9(1): 22-30. 
  
Sinnamon, M. J., et al. (2008). "Matrix metalloproteinase-9 contributes to intestinal 
tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse." Int J Exp 
Pathol 89(6): 466-475. 
  
Sternlicht, M. D. and Z. Werb (2001). "How matrix metalloproteinases regulate cell behavior." 
Annual review of cell and developmental biology 17: 463-516. 
  
Stetler-Stevenson, W. G., et al. (1989). "The activation of human type IV collagenase 
proenzyme. Sequence identification of the major conversion product following organomercurial 
activation." The Journal of biological chemistry 264(3): 1353-1356. 
  
Sun, Y., et al. (1999). "p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) 
gene expression." The Journal of biological chemistry 274(17): 11535-11540. 
  
Tago, K., et al. (2014). "Arf tumor suppressor disrupts the oncogenic positive feedback loop 
including c-Myc and DDX5." Oncogene. 
  
62 
Talora, C., et al. (2005). "Constitutively active Notch1 induces growth arrest of HPV-positive 
cervical cancer cells via separate signaling pathways." Experimental cell research 305(2): 343-
354. 
  
Talora, C., et al. (2005). "Constitutively active Notch1 induces growth arrest of HPV-positive 
cervical cancer cells via separate signaling pathways." Exp Cell Res 305(2): 343-354. 
  
Talora, C., et al. (2002). "Specific down-modulation of Notch1 signaling in cervical cancer cells 
is required for sustained HPV-E6/E7 expression and late steps of malignant transformation." 
Genes & development 16(17): 2252-2263. 
  
Terzic, J., et al. (2010). "Inflammation and colon cancer." Gastroenterology 138(6): 2101-2114 
e2105. 
  
Tian, H., et al. (2015). "DNA damage response--a double-edged sword in cancer prevention and 
cancer therapy." Cancer Lett 358(1): 8-16. 
  
Tian, H., et al. (2015). "DNA damage response--a double-edged sword in cancer prevention and 
cancer therapy." Cancer letters 358(1): 8-16. 
  
Ullman, T. A. and S. H. Itzkowitz (2011). "Intestinal inflammation and cancer." 
Gastroenterology 140(6): 1807-1816. 
  
van den Oord, J. J., et al. (1997). "Expression of gelatinase B and the extracellular matrix 
metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin." 
Am J Pathol 151(3): 665-670. 
  
Van den Steen, P. E., et al. (2002). "Cleavage of denatured natural collagen type II by neutrophil 
gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the 
formation of remnant epitopes in rheumatoid arthritis." FASEB journal : official publication of 
the Federation of American Societies for Experimental Biology 16(3): 379-389. 
  
van Es, J. H., et al. (2005). "Notch/gamma-secretase inhibition turns proliferative cells in 
intestinal crypts and adenomas into goblet cells." Nature 435(7044): 959-963. 
  
Vandooren, J., et al. (2013). "Biochemistry and molecular biology of gelatinase B or matrix 
metalloproteinase-9 (MMP-9): the next decade." Critical reviews in biochemistry and molecular 
biology 48(3): 222-272. 
  
Viennois, E., et al. (2016). "Critical role of PepT1 in promoting colitis-associated cancer and 
therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine 
model." Cellular and molecular gastroenterology and hepatology 2(3): 340-357. 
  
Vilen, S. T., et al. (2013). "Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell 
carcinoma." TheScientificWorldJournal 2013: 920595. 
  
63 
Visse, R. and H. Nagase (2003). "Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases: structure, function, and biochemistry." Circulation research 92(8): 827-839. 
  
Vu, T. H. and Z. Werb (2000). "Matrix metalloproteinases: effectors of development and normal 
physiology." Genes Dev 14(17): 2123-2133. 
  
Waldner, M. J. and M. F. Neurath (2015). "Mechanisms of Immune Signaling in Colitis-
Associated Cancer." CMGH Cellular and Molecular Gastroenterology and Hepatology 1(1): 6-
16. 
  
Walter, L., et al. (2013). "Role of matrix metalloproteinases in inflammation/colitis-associated 
colon cancer." Immunogastroenterology 2: 22-28. 
  
Walter, L., et al. (2017). "Epithelial derived-matrix metalloproteinase (MMP9) exhibits a novel 
defensive role of tumor suppressor in colitis associated cancer by activating MMP9-Notch1-
ARF-p53 axis." Oncotarget 8(1): 364-378. 
  
Waris, G. and H. Ahsan (2006). "Reactive oxygen species: role in the development of cancer and 
various chronic conditions." Journal of carcinogenesis 5: 14. 
  
Wasylyk, C., et al. (1991). "The c-Ets oncoprotein activates the stromelysin promoter through 
the same elements as several non-nuclear oncoproteins." The EMBO journal 10(5): 1127-1134. 
  
Weber, S. and P. Saftig (2012). "Ectodomain shedding and ADAMs in development." 
Development 139(20): 3693-3709. 
  
Woessner, J. F., Jr. (1991). "Matrix metalloproteinases and their inhibitors in connective tissue 
remodeling." FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 5(8): 2145-2154. 
  
Xavier, R. J. and D. K. Podolsky (2007). "Unravelling the pathogenesis of inflammatory bowel 
disease." Nature 448(7152): 427-434. 
  
Xue, M., et al. (2006). "Targeting matrix metalloproteases to improve cutaneous wound healing." 
Expert opinion on therapeutic targets 10(1): 143-155. 
  
Yabluchanskiy, A., et al. (2013). "Matrix metalloproteinase-9: Many shades of function in 
cardiovascular disease." Physiology 28(6): 391-403. 
  
Yoshioka, K., et al. (2015). "Development of cancer-initiating cells and immortalized cells with 
genomic instability." World J Stem Cells 7(2): 483-489. 
  
Zindy, F., et al. (2003). "Arf tumor suppressor promoter monitors latent oncogenic signals in 
vivo." Proceedings of the National Academy of Sciences of the United States of America 
100(26): 15930-15935. 
  
64 
Zisman, T. L. and D. T. Rubin (2008). "Colorectal cancer and dysplasia in inflammatory bowel 
disease." World journal of gastroenterology 14(17): 2662-2669. 
  
Zucker, S. and J. Vacirca (2004). "Role of matrix metalloproteinases (MMPs) in colorectal 
cancer." Cancer Metastasis Rev 23(1-2): 101-117. 
  
 
 
